

# CURRICULUM VITAE

## Timothy Fenske MD

**Professor**  
**Department of Medicine**  
**Division of Hematology and Oncology - Medicine**

### OFFICE ADDRESS:

Clinical Cancer Center  
9200 W Wisconsin Ave  
Milwaukee, WI 53226

### EDUCATION:

09/1986 - 05/1990 B.S., Marquette University, Milwaukee, WI  
06/1992 - 06/1994 M.D., University of Wisconsin-Madison Medical School, Madison, WI  
07/1994 - 07/1997 M.S., UW-Madison, Madison, WI  
07/1997 - 05/1999 M.D., University of Wisconsin-Madison Medical School, Madison, WI  
(combined MD/MS degree program)

### POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS:

06/1999 - 06/2002 Resident, Internal Medicine, University of Wisconsin-Madison, Madison, WI  
07/2002 - 06/2005 Fellow, Hematology/Oncology, Washington University School of Medicine / Barnes-Jewish Hospital, St. Louis, MO  
07/2003 - 06/2005 Trainee, Washington University (Hematology Training Grant)  
07/2004 ASCO/AACR Clinical Trials Workshop, Vail, CO  
09/2005 - 05/2007 K30 Clinical Research Scholars Program (CRSP), Medical College of Wisconsin, Milwaukee, WI

### FACULTY APPOINTMENTS:

07/2005 - 07/2011 Assistant Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI  
07/2011 - 06/2018 Associate Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI  
08/2016 - 10/2018 Section Head, Hematologic Malignancies & BMT, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI  
06/2018 - Present Professor, Medicine, Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI

### HOSPITAL STAFF PRIVILEGES:

03/2004 - 09/2005 Barnes Jewish Hospital, St. Louis, MO  
07/2005 - Present Froedtert Memorial Lutheran Hospital, Milwaukee, WI

### SPECIALTY BOARDS AND CERTIFICATION:

<u>Board Certified</u>	<u>Issue Date</u>	<u>Expiration</u>
Internal Medicine	08/2002	08/2012
Medical Oncology	11/2005	11/2015

<u>Certificates</u>	<u>Issued By</u>	<u>Issue Date</u>	<u>Expiration</u>
CPR	AHA	09/1998	07/2005

ACLS	AHA	05/1999	07/2005
<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Wisconsin License	42635 - 20	09/08/2000	10/31/2025
Drug Enforcement Administration (DEA)		01/22/2003	09/30/2025
Missouri License		10/2003	01/2006

**AWARDS AND HONORS:**

05/1990 Phi Beta Kappa, Marquette University  
05/1990 Graduated Summa Cum Laude, Marquette University  
10/2003 Awarded student loan repayment benefits through the NIH  
08/2010 QuantiaMD 5-Star Award for Excellence in Medical Education  
10/2011 - 10/2012 Best Doctors® 2011-2012  
2011 - 2016 Peer Recognition for Best Doctors® for 6 consecutive years  
06/2012 Murphy Award for Clinical Excellence , Medical College of Wisconsin  
2012 - 2016 Voted a "Top Doctor" by Milwaukee Magazine for 5 consecutive years  
2017 Teaching Award - Bone Marrow Transplant Medical Student Rotation, Medical College of Wisconsin

**MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:**

07/1999 - 07/2001 American College of Physicians – Internal Medicine (Member)  
07/2003 - Present American Society of Hematology (Member)  
07/2004 - 07/2005 American Association for Cancer Research (Member)  
09/2005 - Present Eastern Cooperative Oncology Group (Member)  
08/2009 - Present Wisconsin Oncology Network (Member)

**EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:**

Editorial Board

2012 - Present World Journal of Transplantation  
2015 - Present Annals of Oncology  
2016 - Present Acta Haematologica  
2018 - Present Clinical Lymphoma, Myeloma and Leukemia

Ad-Hoc Reviewer

2006 - Present Ophthalmic Plastic and Reconstructive Surgery  
2009 - Present Clinical Lymphoma and Myeloma  
2010 - Present Therapeutic Advances in Hematology  
2011 - Present Leukemia and Lymphoma  
2012 - Present Cancer  
2013 - Present American Journal of Hematology  
2013 - 2018 Annals of Oncology  
2014 - Present Blood  
2014 - Present Leukemia  
2015 - Present New England Journal of Medicine  
2015 - Present Journal of Clinical Oncology  
2015 - Present Blood Reviews  
2019 - Present Blood Advances  
2021 - Present Transplant and Cellular Therapy

**NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS:**

12/2007 Session Chair, Clinical Results – Autologous Transplantation, American Society of Hematology Annual Meeting  
11/2009 - Present Member, Eastern Cooperative Oncology Group, Lymphoma Committee  
2010 Abstract Reviewer and Session Chair, Clinical Results – Autologous Transplantation, American Society of Hematology Annual Meeting

2010 - Present MCW Institutional Principal Investigator, Wisconsin Oncology Network  
 04/2011 Symposium Committee Co-Chair and Moderator, 8th International Chicago Lymphoma Symposium  
 10/2011 - 03/2012 Co-program director and speaker, 1st Annual Controversies of Hematologic Malignancies Symposium (Milwaukee, WI)  
 10/2011 - Present MCW Institutional PI, Eastern Cooperative Oncology Group  
 2011 - 2012 Member, Data Review Committee, Bone Marrow Transplantation Clinical Trials Network Protocol 0401.  
 04/2012 Symposium Committee Co-Chair and Moderator, 9th International Chicago Lymphoma Symposium  
 04/2013 Symposium Committee Co-Chair and Moderator, 10th International Chicago Lymphoma Symposium  
 2013 - 2014 Member, Lymphoma Committee, 2014 State of the Science Symposium, Blood and Marrow Transplant Clinical Trials Network  
 02/2014 - Present Abstract Reviewer and Session Chair, "Allogeneic Transplants & Autologous Transplants", 2014 BMT Tandem Meetings  
 2014 - 2015 2016 Symposium Committee Co-Chair and Organizer, Ultmann International Chicago Lymphoma Symposium  
 2014 - 2016 Co-Chair and Organizer, Symposium Committee, Ultmann International, Chicago Lymphoma Symposium  
 03/2015 - 03/2020 Co-Chair, Lymphoma Working Committee, Center for International Blood and Marrow Transplant Research  
 03/2015 - 03/2020 Lymphoma Working Committee Co-Chair, Center for International Blood  
 04/2016 - Present Lymphoma Steering Committee, National Cancer Institute  
 2016 Abstract Reviewer and Session Chair, American Society of Hematology Annual Meeting, "Clinical Results – Autologous Transplantation"  
 2019 Session Chair, "Aggressive Lymphoma – Results from retrospective/ observational studies", American Society of Hematology Annual Meeting  
 2022 Co-Chair and Moderator, Symposium Committee, 19th International Ultmann Lymphoma Symposium (Chicago, IL)  
 2023 Co-Chair and Moderator, Symposium Committee, 20th International Ultmann Lymphoma Symposium (Chicago, IL)

**RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:**

**Active**

**Peer Review**

Title:	A randomized placebo-controlled phase III study of ibrutinib maintenance following autologous stem cell transplantation in high-risk patients with relapsed or refractory diffuse large B-Cell lymphoma.
Source:	U.S. Intergroup Study
Role:	BMT-CTN Study Co-Chair
Dates:	2015 - Present
Title:	A Randomized Phase III Trial of Consolidation with Autologous Hematopoietic Cell Transplantation Followed by Maintenance Rituximab vs. Maintenance Rituximab Alone for Patients with Mantle Cell Lymphoma in Minimal Residual Disease-Negative First Complete Remission.
Source:	U.S. Intergroup Study
Role:	National Principal Investigator and Lead Investigator for a companion BIQSFP
Dates:	2016 - Present

Direct Funds: \$1,198,193 (For the minimal residual disease testing integral to the trial, funded through the BIQSFP grant. (Biomarker, Imaging and Quality of Life Studies Funding Program) grant)

**Prior**

**Peer Review**

Title: Development of 99mTc scanning as a quantitative in vivo assay to predict chemotherapy drug resistance and clinical outcome in lymphoma patients.

Source: Medical College of Wisconsin, Clinical Cancer Center

Role: Principal Investigator

PI: Fenske, Timothy

Dates: 10/2007 - 06/2011

Direct Funds: \$40,000 (Accrual goal (21 pts) met in May 2010. )

Title: A phase II study of bortezomib and temsirolimus for relapsed or refractory B-cell non-Hodgkin lymphoma.

Source: Millennium / Takeda Pharmaceuticals

Role: Principal Investigator

PI: Fenske, Timothy

Dates: 09/01/2010 - 08/31/2013

Direct Funds: \$485,000 (Was ultimately published in Cancer in 2014)

Title: Rituximab with combination chemotherapy or bendamustine hydrochloride followed by consolidation chemotherapy and stem cell transplantation in older patients with previously untreated mantle cell lymphoma.

Source: U.S. Intergroup Study S1106

Role: ECOG Study Chair

Dates: 2011 - 2014

**Non-Peer Review**

Title: Outcome of patients with Burkitt lymphoma treated at two academic medical centers between 1996 and 2008.

Source: Departmental, collaboration with Washington University

Role: Principal Investigator

PI: Fenske, Timothy

Dates: 2009 - 2011

Direct Funds: \$1,500 (Froedtert Foundation)

**INVITED LECTURES/WORKSHOPS/PRESENTATIONS:**

**Local**

Extranodal MALT lymphoma, Medical College of Wisconsin Division of Gastroenterology Case Conference,

Milwaukee, WI, 03/2006  
 Non-Hodgkin Lymphoma, MCW/Froedtert Community Health Lecture Series, Milwaukee, WI, 09/2007  
 Lymphoma Transplant, Hematology Update, Medical College of Wisconsin, Milwaukee, WI, 01/2008  
 Lymphoma Transplant and Hodgkin Lymphoma, Hematology Update, Medical College of Wisconsin, Milwaukee, WI, 01/2009  
 "Lymphoma Overview", lecture given to Physician Assistant students, Marquette University, Milwaukee, WI, 11/2009  
 "CPC" discussant, Medical College of Wisconsin Conference, Milwaukee, WI, 12/07/2009  
 Aggressive NHL and HL, Hematology Update, Medical College of Wisconsin, Milwaukee, WI, 03/31/2010  
 "Lymphoma Overview", lecture given to Physician Assistant students, Marquette University, Milwaukee, WI, 11/2010  
 "Frontline therapy for follicular lymphoma: so many options, so little consensus", Controversies of Hematologic Malignancies Symposium, Milwaukee WI, 03/24/2012  
 "Selected hematopathology cases in leukemia and lymphoma", Controversies of Hematologic Malignancies Symposium, Milwaukee, WI, 03/08/2014  
 "Lymphoma Overview" and "Monitoring for Relapse", 2nd Annual Lymphoma Survivors Meeting, Leukemia & Lymphoma Society, Milwaukee, WI, 04/05/2014  
 "Update in treatment of mantle cell lymphoma", OncLive State of the Science Summit, Milwaukee, WI, 09/2014  
 "Minimal Residual Disease analysis for lymphoma", Hematologic Malignancies and Immunotherapy Research Seminar, 04/27/2017  
 "Mantle cell lymphoma: moving from big guns to magic bullets", MCW Department of Medicine Grand Rounds, Milwaukee, WI, 04/12/2019  
 "Recent developments in treatment of relapsed / refractory mantle cell lymphoma", OncLive State of the Science Summit, Milwaukee, WI, 04/23/2019  
 "Update in treatment of mantle cell lymphoma", Wisconsin Multiple Myeloma and Lymphoma Summit, Binaytara Foundation, Milwaukee, WI, 08/26/2023

### **Regional**

"Chronic Myeloid Leukemia", Lecture given to patients and caregivers, Leukemia and Lymphoma Society, Spring Leukemia/MDS Symposium, Madison, WI, 05/2006  
 "Paving the way for progress: Clinical trials in blood cancers", Leukemia and Lymphoma Society's patient education series, Waukesha, WI, 03/2007  
 "Biology of Cancer" course, LECTURED ON "Clinical oncology and clinical oncology research", UW-Parkside, Kenosha, WI, 03/2008  
 "Aggressive B-cell NHL" lecture, Given to patients and caregivers, as part of the Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison, WI, 05/2009  
 "Aggressive B-cell NHL" lecture, Given to patients and caregivers, as part of the Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison, WI, 03/2010  
 "Biology of Cancer" course, LECTURED ON "Clinical oncology and clinical oncology research", UW-Parkside, Kenosha, WI, 05/2010  
 "Overcoming Barriers to Optimal Treatment of Non-Hodgkin Lymphoma (Clinical Care Options Oncology)", Fox Valley Hematology/Oncology, Appleton, WI, 03/15/2011  
 "Overcoming Barriers to Optimal Treatment of Non-Hodgkin Lymphoma (Clinical Care Options Oncology)", Belin Health, Green Bay, WI, 06/01/2011  
 "Overcoming Barriers to Optimal Treatment of Non-Hodgkin Lymphoma (Clinical Care Options Oncology)", Wheaton Franciscan Healthcare, Racine, WI, 07/12/2011  
 "Overcoming Barriers to Optimal Treatment of Non-Hodgkin Lymphoma (Clinical Care Options Oncology)", Bay Regional Medical Center, Bay City, MI, 08/08/2011  
 "Relapsed and Refractory Diffuse Large B-Cell Lymphoma: Are We Making Any Progress?", Keynote Lecture for Wisconsin Oncology Network Meeting, Madison, WI, 04/2013  
 "Radiographic imaging in lymphoma: benefits and risks", Leukemia and Lymphoma Society Patient and Caregiver Meeting on Lymphoma, Madison, WI, 04/2013  
 "Aggressive B-cell non-Hodgkin lymphomas" and "Mantle cell lymphoma.", Lymphoma Research Foundation Patient and Caregiver Meeting, Chicago IL, 05/2014  
 "What's New in Lymphoma?", Third annual Advances in Hematology and Oncology Symposium, Green Bay, WI, 10/17/2014

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma at regional sales training meeting., 10/2014

“Mantle cell lymphoma”, Unbranded disease-focused presentations given at various sites across the Midwest, 2014 - 2017

“New Developments in Transplant for Lymphoma: A practicing clinician’s view for 2016”, Controversies of Hematologic Malignancies Symposium, Milwaukee WI, 03/05/2016

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma at regional sales training meeting., 11/2016

“New and Nagging Questions in Non-Hodgkin Lymphoma”, 6th annual Advances in Hematology and Oncology Symposium, Green Bay, WI, 10/21/2017

“Debate: Allogeneic transplant has no significant role in the management of classical Hodgkin lymphoma in 2019”, 8th Annual Controversies in Hematologic Malignancies Symposium, 03/09/2019

“Measurable Residual Disease Assessment in Non-Hodgkin Lymphoma”, Appleton, WI, 05/21/2019

“Mantle cell lymphoma: moving from big guns to magic bullets”, Northwestern University, Division of Hematology and Oncology Grand Rounds, Chicago, IL, 06/07/2019

“Measurement of ctDNA/MRD in the management of hematologic malignancies”, 9th Annual Controversies in Hematologic Malignancies Symposium, 02/29/2020

“Update in Cellular Therapy for Hodgkin Lymphoma”, Midwest Cellular Conference: Treatment Options for Advanced Hematologic Malignancies, Chicago, IL, 11/04/2020

“Transplant in Non-Hodgkin’s Lymphoma” unbranded disease-focused presentation., - April 20/16: Glenview, IL - Feb 2017: St Louis, MO - 11/16/17: Green Bay, WI - March 2017: Evanston, IL - 11/16/17: Green Bay, WI - 4/4/18: St. Louis, MO - 5/16/19: St. Louis, MO, 2106 - 2018

### **National**

“Optimizing therapy for CD20-expressing B-cell malignancies: A focus on diffuse large B-cell lymphoma”, RHD, Dallas, TX, 06/2007

Invited to prepare 6 CME oncology case presentations between 09/2009 and 04/2010 for QuantiaMD (an on-line CME company)., Featured in a full-page advertisement in Community Oncology (March 2010 Issue), 2009 - 2010

“Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL”, Clinical Care Options Oncology, - 4/13/10: Lawrence & Memorial Medical Center (New London, CT) -4/28/10: Halifax Medical Center (Daytona Beach, FL) -5/14/10: Union Memorial Hospital (Baltimore, MD) -8/16/10: Covenant Women and Children’s Hospital (Lubbock, TX) -8/30/10: Phelps County Regional Medical Center (Rolla, MO) -9/13/10: Thompson Cancer Survival Center (Knoxville, TN), 04/2010 - 09/2010

Moderator, “Standard Therapy for Younger Patients with Mantle Cell Lymphoma Should Include Stem Cell Transplantation.”, International Chicago Lymphoma Symposium, Chicago, IL, 04/2011

“Workshop With the Experts: Overcoming Barriers to Optimal Treatment of Non- Hodgkin Lymphoma”, Clinical Care Options Oncology, - 06/01/11: Bellin Health (Green Bay, WI) - 07/09/11: Lawrence Memorial Hospital (Lawrence, KS), 06/2011 - 07/2011

“Conventional Therapy and Novel Agents for Follicular Lymphoma”, Educational session at the Bone Marrow Transplantation Tandem Meeting, San Diego, CA, 02/2012

“High Risk Patients with DLBCL Should Undergo a Stem Cell Transplant as Part of Front-line Treatment.”, International Chicago Lymphoma Symposium, Chicago, IL, 04/2012

“Timing of Hematopoietic Stem Cell Transplantation for Follicular Lymphoma.”, 10th International Chicago Lymphoma Symposium, Chicago, IL, 04/27/2013

Moderator, “Patients with mantle cell lymphoma should receive an autotransplant in first remission.”, 11th International Ultmann Chicago Lymphoma Symposium, Chicago, IL, 05/03/2014

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma, national sales training meeting, 10/2014

Member, Lymphoma Committee, Blood and Marrow Transplant Clinical Trials Network State of the Science Symposium, 2014

“Autologous stem cell transplant should be a treatment option for relapsed mantle cell lymphoma.”, 12th International Ultmann Chicago Lymphoma Symposium, Chicago, IL, 04/25/2015

Invited lecture “Diffuse Large B-cell lymphoma: How do we move forward?”, Hematology/Oncology Grand Rounds, Houston Methodist Hospital, 06/02/2015

“Transplant and Non-Hodgkin Lymphoma”, Product Theater presentation, 2016 BMT Tandem meeting, Honolulu, HI, 02/20/2016

Moderator, “No role for surveillance imaging in lymphoma.”, 13th International Ultmann Chicago Lymphoma Symposium, Chicago, IL, 05/06/2016

Invited lecturer for Celgene to educate sales force regarding mantle cell lymphoma, national sales training meeting, 11/2016

“Transplant in Non-Hodgkin Lymphoma”, unbranded lecture, - Jan 2016: Consultant to develop slide set - Sept 2016: San Francisco, CA - 6/1/17: Santa Rosa, CA - 12/10/17: Atlanta, GA - 8/6/18: Denver, CO, 2016 - 2018

“The Healthy Days Initiative: Moving Toward Personalized Lymphoma Therapy for Relapsed/Refractory Follicular Lymphoma”, CME program, - 10/28/16: Montefiore Medical Center (New York City, New York) - 11/4/16: Washington Cancer Institute (Washington, DC) - 4/24/17: NH Forsyth Medical Center (Winston-Salem, NC), 2016 - 2017

Invited lecturer, “Best of ASH” symposium at Cleveland Clinic, Cleveland, OH, 01/25/2017

Presenter, “Meet the Professor” session, “Unusual Lymphomas and the Role of Autografting and Allografting.”, 2017 ASBMT Annual Meeting, Orlando, Florida, 02/23/2017

Invited lecturer on “What is the best first-line therapy for younger patients with mantle cell lymphoma?”, Great Debates & Updates in Hematologic Malignancies, New York City, NY, 04/08/2017

Invited lecturer on “Next Generation Sequencing-based Minimal Residual Disease Analysis in B- cell lymphomas.”, Eastern Cooperative Oncology group meeting, Hematologic Malignancies session, Washington, D.C., 05/05/2017

“New developments in transplant for lymphoma”, University of Kansas, Kansas City, KS, 08/31/2017

“Minimal residual disease analysis in lymphoma patients.”, Atlanta, GA, 12/09/2017

“Future directions in mantle cell lymphoma.”, 15th International Ultmann Chicago Lymphoma Symposium, Chicago, IL, 05/05/2018

“Choice of allogeneic vs autologous HSCT in early relapsed NHL and double hit lymphoma.”, 4th International Workshop on the Biology, Prevention, and Treatment of Relapse after Hematopoietic Stem Cell Transplantation, Chicago, IL, 09/21/2018

“Frontline therapy for mantle cell lymphoma: to transplant or not to transplant?”, Case-based education session, American Society of Clinical Oncology, Chicago, IL, 06/02/2019

“Best of ASH – Lymphoma and CLL”, University of Texas, San Antonio, TX, 2019 - 2024

“Maintenance rituximab in mantle cell lymphoma: where do we stand in 2021?”, Pan-Pacific Lymphoma Conference, Kona, Hawaii, 08/12/2021

“Autologous stem cell transplant is the preferred first-line treatment option for mantle cell lymphoma.”, 19th International Ultmann Lymphoma Symposium, Chicago, IL, 04/2022

“Is stem cell transplantation still necessary in frontline mantle cell lymphoma?”, Society of Hematologic Oncology meeting, Houston, TX, 09/08/2023

### **International**

“Debate: Is there any role for HCT in relapsed/ refractory FL in 2022?”, First World Congress on Controversies in Lymphoma (COLYM), Barcelona Spain, 10/2022

### **COMMITTEE SERVICE:**

#### **Medical College of Wisconsin**

2007 - 2009 Member, Hematology/Oncology Fellowship Admission Committee, Hematology and Oncology, Medicine, Medical College of Wisconsin

10/2008 - 04/2010 Member, Institutional Review Board (IRB), Froedtert & Medical College of Wisconsin

2012 - 2019 Chair, MCW Cancer Center Leukemia, Lymphoma and Myeloma Faculty Disease Committee, Medical College of Wisconsin

04/2013 Director, 2nd Annual Controversies in Hematologic Malignancies Conference, Medical College of Wisconsin

2013 - 2017 Member, MCW Cancer Center Scientific Review Committee, Medical College of Wisconsin

05/2014 Director, 2nd Annual Lymphoma Survivors Conference, Leukemia & Lymphoma Society, Medical College of Wisconsin

2017 - 2019 Cancer Clinical Program Leadership Committee, Medical College of Wisconsin

2019 - Present Chair, MCW Cancer Center Lymphoma Disease Team, Medical College of Wisconsin

## **MEDICAL COLLEGE TEACHING ACTIVITIES:**

### **Community/Lay Public**

04/2010 "Hodgkin lymphoma" and "Non-Hodgkin lymphoma" lectures given to MCW Division of Hematology and Oncology Clinical Research Coordinators

### **Medical Student Education**

2006 Instructor in the "Clinical Examining and Reasoning" course for the MCW second-year medical students

2007 Instructor in the "Clinical Examining and Reasoning" course for the MCW second-year medical students

2009 Instructor in the "Clinical Examining and Reasoning" course for the MCW second-year medical students

2010 - 2011 Instructor in the "General Principles" Module of the M1 Curriculum, "Neoplasia and Carcinogenesis"

2011 - 2017 Instructor in the "Hematology Neoplasia" Module of the M2 Integrated Curriculum

### **Resident and Fellow Education**

2005 - 2023 Instruction of fourth-year medical students, interns, residents, and fellows rotating through the inpatient Heme/Onc service, Oncology consultation service, and outpatient Heme/Onc clinic

2005 - 2023 "Lymphoma for the Internist" lecture given at MCW (1-2 times per year) Resident Noon Conference Series

2006 - 2013 "Hodgkin Lymphoma" lecture given to the Heme/Onc fellows as part of the core curriculum series.

2008 - 2013 "Aggressive Non-Hodgkin Lymphoma" lecture given to the Heme/Onc fellows as part of the core curriculum series.

2008 - 2014 "Low-grade Non-Hodgkin Lymphoma" lecture given to the Heme/Onc fellows as part of the core curriculum series.

2009 - 2014 "Clinicopathologic Case Conference" lectures given to Medicine Residents.

2014 "Autologous hematopoietic cell transplantation" lecture given to the Heme/Onc fellows as part of the core curriculum series.

2016 "Autologous hematopoietic cell transplantation" lecture given to the Heme/Onc fellows as part of the core curriculum series.

### **Continuing Medical Education**

01/2008 "Lymphoma Transplant", Hematology Update

01/2009 "Lymphoma Transplant and Hodgkin Lymphoma", Hematology Update

03/31/2010 "Aggressive NHL and HL", Hematology Update

## **EXTRAMURAL TEACHING:**

### **Community/Lay Public**

05/2006 Spring Leukemia/MDS Symposium, Madison, WI, "Chronic Myeloid Leukemia" lecture given to patients and caregivers, Leukemia and Lymphoma Society

03/2007 Leukemia and Lymphoma Society's patient education series, Waukesha, WI, "Paving the way for progress: Clinical trials in blood cancers"

09/2007 Froedtert/ MCW Community Health series, "Non-Hodgkin Lymphoma" lecture

05/2009 Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison, WI, "Aggressive B-cell NHL", lecture given to patients and caregivers

2010 Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison, WI, "Aggressive B-cell NHL", lecture given to patients and caregivers

2013 Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium, Madison, WI, "Aggressive B-cell NHL", lecture given to patients and caregivers

04/2014 Leukemia & Lymphoma Society, Wisconsin Chapter (Milwaukee, WI), Director, "Lymphoma Survivorship Conference"

10/2014 Lymphoma Research Foundation, "Aggressive NHL", Patient Forum

05/2015 Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium (Madison, WI), "Clinical Trials in Lymphoma" lecture given to patients and caregivers



- 09/2016 Leukemia and Lymphoma Society's spring Leukemia/Lymphoma symposium (Milwaukee, WI), "Aggressive Non-Hodgkin lymphomas and Hodgkin lymphoma" lecture given to patients and caregivers
- 10/2016 Lymphoma Research Foundation's North American Educational Forum on Lymphoma (Chicago, IL), "Diffuse Large B-Cell Lymphoma and other Aggressive B-cell lymphomas" lecture given to patients and caregivers
- 09/2019 Lymphoma Research Foundation Patient Education Series, "Ask the Doctor: Updates on Lymphoma and CLL, and Treatment Options"
- 11/2021 Lymphoma Research Foundation Patient Education Series, "Ask the Doctor: Mantle cell lymphoma"
- 09/2022 Lymphoma Research Foundation Patient Education Series, "Ask the Doctor: Mantle cell lymphoma"

### **Medical Student Education**

- 2001 University of Wisconsin Medical School, Instructor in second-year medical student Hematology course
- 2004 - 2005 Washington University School of Medicine, Instructor in second-year medical student Hematology course
- 03/2008 - 05/2010 UW-Parkside, Kenosha, WI, "Biology of Cancer" course at UW-Parkside. Lectured on "Clinical oncology and clinical oncology research"
- 2009 - 2022 Marquette University, "Lymphoma Overview" 2 lecture series given each year, to Physician Assistant students.

### **Continuing Medical Education**

- 06/2007 RHD Medical Center Grand Rounds, Dallas, TX, Optimizing therapy for CD20-expressing B-cell malignancies: A focus on diffuse large B-cell lymphoma"
- 09/2009 - 04/2010 QuantiaMD (A CME web site), Presented six educational oncology cases
- 2010 -4/28/10: Halifax Medical Center (Daytona Beach, FL) -5/14/10: Union Memorial Hospital (Baltimore, MD) -8/16/10: Covenant Women and Children's Hospital (Lubbock, TX) -9/13/10: Thompson Cancer Survival Center (Knoxville, TN), "Spanning the Continuum of Care: Optimizing Patient Outcomes in NHL" (Clinical Care Options Oncology)
- 2011 -06/01/11: Bellin Health (Green Bay, WI) -07/09/11: Lawrence Memorial Hospital (Lawrence, KS), "Workshop With the Experts: Overcoming Barriers to Optimal
- 2016 -10/28/16: Montefiore Medical Center (New York City, New York) -11/4/16: Washington Cancer Institute (Washington, DC) -4/24/17: NH Forsyth Medical Center (Winston-Salem, NC), "The Healthy Days Initiative: Moving Toward Personalized Lymphoma Therapy for Relapsed/Refractory Follicular Lymphoma"
- 2017 - 2022 At least 5 pharma-sponsored lectures per year on topics relating to non-Hodgkin lymphoma, CLL, and bone marrow/stem cell transplantation

### **Nursing Student Education**

- 06/2014 Froedtert Hospital, "Autologous Hematopoietic Cell Transplantation," lecture given to Froedtert Hospital inpatient Heme/Onc RNs.
- 01/2015 Froedtert Hospital, "Lymphoma" lecture given to Froedtert Hospital inpatient and outpatient Heme/Onc RNs.

## **MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED:**

### **Medical Students**

- Stacy Parker, Medical College of Wisconsin, 2009 Mentored in writing a case series
- Sara Torgerson, Medical College of Wisconsin, 2009 - 2010 Mentored in writing a case report
- Terence Mukonje, Medical College of Wisconsin, 04/2010 - Present shadow in outpatient clinic (04/2010 - present), and mentoring in writing a case report (2010).
- Amy Braden, Medical College of Wisconsin, 2010 - 2011 Mentoring in analyzing a retrospective case series
- Sirisha Paruchuri, Medical College of Wisconsin, 2010 Mentoring in writing a case report

### Clinical/Research Fellows

- Christopher Hake, Medical College of Wisconsin, 2007 - 2008 Mentored in writing a review article  
Leena Varkey, Medical College of Wisconsin, 2011 Mentoring in writing a review article on Aggressive B-cell non-Hodgkin Lymphoma for Hospital Physician Hematology Board Review Manual  
Ravi Pingali, Medical College of Wisconsin, 2011 - 2012 Mentoring in analyzing and writing up a case series on autologous stem cell transplantation for mantle cell lymphoma  
Robert Cornell, Medical College of Wisconsin, 2011 Mentoring in writing a review article on Low Grade non-Hodgkin Lymphoma for Hospital Physician Hematology Board Review Manual

### Residents

- Heather Benjamin, Medical College of Wisconsin, 2008 Mentored in writing a case report  
Tara Kroll, Medical College of Wisconsin, 2009 - 2010 Mentored in writing a case report  
Brian Aebly, Medical College of Wisconsin, 2009 - 2010 Mentoring in writing a case report  
Laura Farrington, Medical College of Wisconsin, 2009 - 2010 Mentoring in analyzing and writing up a large retrospective series of Burkitt lymphoma

## BIBLIOGRAPHY

### Refereed Journal Publications/Original Papers

1. **Fenske TS**, Baxter-Lowe LA. Characterization of a novel DQB1 allele associated with HLADQw3: Implications for oligotyping. *Human Immunology* 33: 224-227, 1992.
2. **Fenske TS**, Baxter-Lowe LA. Two novel HLA-DQB1\*06 alleles reveal additional heterogeneity of HLA-DQw1. *Tissue Antigens* 40: 49-52, 1992.
3. Farner NL, Gan J, de Jong JLO, Leary TP, **Fenske TS**, Buckley P, Dunlap S, Sondel PM. Alteration of the CD34+ Tf-1b cell line profile in response to long-term exposure to IL-15. *Cytokine* 9 (5): 316-27, 1997.
4. Monson NL, **Fenske TS** (published incorrectly as "**Fenske TJ**"), Wei S, Okragly AJ, de Jong JL, Haak-Frendscho M, O'Shea J, Djeu J, Sondel PM. A p74 common gamma receptor chain isoform facilitates IL-2 and IL-15 responses by the myelomonocytic cell line, Tf-1?2. *Journal of Leukocyte Biology* 69(3):419-25, 2001.
5. **Fenske TS**, Pengue G, Mathews V, Hanson PT, Hamm SE, Riaz N, Graubert TA. Stem cell expression of the AML1/ETO fusion protein induces a myeloproliferative disorder in mice. *Proceedings of the National Academy of Sciences of the United States of America* 101(42): 15184-9, 2004.
6. **Fenske TS**, Kahl BS, Eickhoff J, Mitchell TL, Smith EP, Atkinson E, Garry McCoy A, Eckstein L, Flynn B, McMannes J, Howard S, Longo WL. Excessive toxicity of the high dose thiotepa and etoposide regimen when combined with radiation: long-term autologous transplantation experience in follicular and mantle cell lymphoma. *Leukemia and Lymphoma* 46(10): 1441-8, 2005.
7. **Fenske TS**, McMahan, C, Edwin D, Jarvis JC, Cheverud JM, Minn M, Mathews V, Bogue MA, Province MA, McLeod HL, Graubert TA. Identification of candidate alkylator-induced cancer susceptibility genes by whole genome scanning in mice. *Cancer Research* 66(10): 5029-38, 2006.
8. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the Treatment of Patients with Very High-Titer Acquired Factor VIII Inhibitors Refractory to Conventional Chemotherapy. *Haemophilia* 13(1): 46-50, 2007.
9. **Fenske TS**, Benjamin H, Kroft SH, Hohenwarter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the the liver with yttrium-90 microsphere embolization. *Nature Clinical Practice Oncology* 5(11): 677-81, 2008.
10. Parker SM, Olteanu H, VanTuinen P, Lawton CA, Schultz CJ, Christians KK, **Fenske TS**. Follicular lymphoma transformation to dual translocated Burkitt-like lymphoma: improved disease control associated with radiation therapy. *International Journal of Hematology* 90(5): 616-622, 2009.
11. **Fenske TS**, Hari PN, Carreras J, Zhang MJ, Kamble RT, Bolwell BJ, Cairo MS, Champlin RE, Chen YB, Freytes CO, Gale RP, Hale GA, Ilhan O, Khoury HJ, Lister J, Maharaj D, Marks DI, Munker R, Pecora AL, Rowlings PA, Shea TC, Stiff P, Wiernik PH, Winter JN, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Impact of pre-transplant rituximab on survival after autologous hematopoietic stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). *Biology of Blood and Marrow Transplantation* 15(11): 1455-64, 2009.
12. Kroll T, Ames M, **Fenske TS**. Successful management of pregnancy occurring in a chronic myeloid leukemia patient on dasatinib. *Leukemia and Lymphoma* 51(9): 1-3, 2010

13. Torgerson S, Tinguely M, **Fenske TS**. Intracranial Hodgkin lymphoma: case report and review of the literature. *Journal of Neuro-oncology* 102(2): 329-334 (2011)
14. Olteanu H, **Fenske TS**, Harrington AM, Kroft SH. CD23 expression in follicular lymphoma: clinicopathologic correlations. *American Journal of Clinical Pathology* 135(1): 46-53, 2011
15. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, Schneider SE, Keppel CR, Wagner-Johnston NW, Carson K, Bartlett NL. A phase II multicenter study of lenalidomide in relapsed or refractory classical Hodgkin lymphoma. *Blood* 118(19): 5119-25 (2011)
16. Bacher U, Klyuchnikov E, Le-Rademacher J, Carreras J, Armand P, Bishop MR, Bredeson CN, Cairo MS, **Fenske TS**, Freytes CO, Gale RP, Gibson J, Isola LM, Inwards DJ, Laport GG, Lazarus HM, Maziarz RT, Wiernik PH, Schouten HC, Slavin S, Smith SM, Vose JM, Waller EK, Hari PN. Conditioning regimens for allotransplant for diffuse large B-cell lymphoma – myeloablative or reduced intensity? *Blood Epub ahead of print*, Sept 24 (2012)
17. Osmanov EA, Hong X, Scheliga A, Mayer J, Offner F, Rule S, Teixeira A, Walewski J, de Vos S, Crump M, Shpilberg O, Esseltine DL, Zhu E, Enny C, Theocharous P, van de Velde H, Elsayed YA, Zinzani PL; LYM-3001 study investigators. Bortezomib plus rituximab versus rituximab alone in patients with relapsed, rituximab-naïve or rituximab-sensitive, follicular lymphoma: a randomised phase 3 trial. *Lancet Oncology* 12: 773-84, 2011. [Listed as one of 179 "collaborators," but not as an author].
18. \*Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, **Fenske TS**, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JL. Autologous and allogeneic transplantation for Burkitt lymphoma outcomes and changes in utilization: a report from the Center for International Blood and Marrow Transplant Research. *Biology of Blood and Marrow Transplantation*, 19(2): 173-9, 2013.
19. Hamadani H, Saber W, Ahn KW, Carreras J, Cairo MS, **Fenske TS**, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Lazarus HM. Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the Center for International Blood and Marrow Transplant Research. *Biology of Blood and Marrow Transplantation* 19(4): 625-31, 2013.
20. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, **Fenske TS**, Gale RP, Gibson J, Hale GA, Hari PN, Hsu JW, Inwards DJ, Kamble RT, Klein A, Maharaj D, Marks DI, Rizzieri DA, Savani BN, Schouten HC, Waller EK, Wirk B, Laport GG, Montoto S, Maloney DG, Lazarus HM. Impact of pretransplantation conditioning regimens on outcomes of allogeneic transplantation for chemotherapy-unresponsive diffuse large B-cell lymphoma and grade III follicular lymphoma. *Biology of Blood and Marrow Transplantation*, 19(5): 746-53, 2013.
21. Vose JM, Carter S, Burns LJ, Ayala E, Press OW, Moskowitz CH, Stadtmauer EA, Mineshi S, Ambinder R, **Fenske T**, Horowitz M, Fisher R, Tomblyn M. Phase III randomized study of rituximab/ carmustine, etoposide, cytarabine, melphalan (BEAM) compared with 131-iodine tositumomab/ BEAM with autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma: results from the BMT CTN 0401 Trial. *Journal of Clinical Oncology* 31(13): 1662-68, 2013.
22. \*Cornell RF, Hari P, Zhang MJ, Zhong X, Thompson J, **Fenske TS**, Morowitz MM, Komorowski R, Palmer J, Pasquini MC, Rizzo JD, Saber W, Thomas M, Drobyski WR. Divergent effects of novel immunomodulatory agents and cyclophosphamide on the incidence of engraftment syndrome after transplantation for multiple myeloma. *Biology of Blood and Marrow Transplantation* 19(9): 1368-73, 2013.
23. Maziarz RT, Wang Z, Zhang MJ, Bolwell BJ, Chen A, **Fenske TS**, Freytes CO, Gale RP, Gibson J, Hayes-Lattin BM, Holmberg L, Inwards DJ, Isola LM, Khoury HJ, Lewis VA, Maharaj D, Munker R, Phillips GL, Rizzieri DA, Rowlings PA, Saber W, Satwani P, Waller EK, Maloney DG, Montoto S, Laport GG, Vose JM, Lazarus HM, Hari PN. Autologous hematopoietic cell transplantation for non-Hodgkin lymphoma with secondary CNS involvement. *British Journal of Haematology* 162(5): 648-56, 2013.
24. Smith SM, Burns LJ, van Besien K, LeRademacher J, He W, **Fenske TS**, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PN. Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma. *Journal of Clinical Oncology* 31(25): 3100-9, 2013.
25. **Fenske TS**, Zhang MJ, Carreras J, Ayala E, Burns LJ, Cashen AF, Costa LJ, Freytes CO, Gale RP, Hamadani M, Holmberg L, Inwards DJ, Lazarus HM, Maziarz RT, Munker R, Perales M, Rizzieri DA,

- Schouten HC, Smith SM, Waller EK, Wirk BM, Laport GG, Montoto S, Maloney DG, Hari PN. Autologous or reduced-intensity allogeneic hematopoietic cell transplantation for chemotherapy-sensitive mantle cell lymphoma: analysis of transplant timing and modality. *Journal of Clinical Oncology* 32(4): 273-81, 2014.
26. \*Farrington L, Wildes TM, Yeung C, Harrington AM, Foyil KV, Liu J, Kreisel F, Bartlett NL, **Fenske TS**. Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two U.S. academic medical centers. *Therapeutic Advances in Hematology* 5(1): 3-12, 2014.
27. Wirk B, **Fenske TS**, Hamadani M, Hu Z, Akpek G, Aljurf MD, Armand P, Ayala E, Bachanova V, Bolwell BJ, Cairo MS, Cashen A, Chen Y, Costa LJ, Farhan S, Freytes CO, Gajewski JL, Gibson J, Hale GA, Holmberg LA, Hsu JW, Inwards DJ, Kamble RT, Maharaj D, Maziarz RT, Munker R, Nath R, Reddy NM, Reeder CB, Rizzieri DA, Sauter CS, Savani BN, Schouten HC, Sureda A, Vose JM, Waller ED, Wiernik PH, Gale RP, Burns LJ, Saber W. Outcomes of hematopoietic cell transplantation for diffuse large B cell lymphoma transformed from follicular lymphoma. *Biology of Blood and Marrow Transplantation* 20(7): 951-9, 2014
28. \*Pingali R, Jewell S, Havlat L, Bast M, Thompson J, Eastwood D, Bartlett NL, Armitage JO, Wagner-Johnston N, Vose JM, **Fenske TS**. Limited clinical utility of routine surveillance imaging in classical Hodgkin lymphoma patients in first complete remission. *Cancer* 120(14): 2122-9, 2014.
29. Gandhi M, Evens AM, **Fenske TS**, Hamlin P, Coiffier B, Engert A, Moskowitz AJ, Ghosh N, Petrich AM, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio SM, Raisch DW, West DP, Gordon LI, Winter JN. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. *Blood* 123(18): 2895-7, 2014.
30. Hamadani M, Hari PN, Zhang Y, Carreras J, Akpek G, Aljurf MD, Ayala E, Bachanova V, Chen AI, Chen Y, Costa LJ, **Fenske TS**, Freytes CO, Ganguly S, Hertzberg MS, Holmberg LA, Inwards DJ, Kamble RT, Kanfer E, Lazarus HM, Marks DI, Nishihori T, Olsson R, Reddy NM, Rizzieri DA, Savani BN, Solh M, Vose JM, Wirk B, Maloney DG, Smith SM, Montoto S, Saber W. Early failure of frontline rituximab-containing chemoimmunotherapy in diffuse large B-cell lymphoma does not predict futility of autologous hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 20(11): 1729-36, 2014.
31. Petrich AM, Gandhi M, Jovanovic B, Castillo J, Rajguru S, Yang DT, Shah KA, Whyman JD, Lansigan FL, Hernandez-Ilizaliturri FJ, Lee LX, Barta SK, Melinamani S, Karmali R, Adeimy C, Smith S, Dalal N, Nabhan C, Peace D, Vose J, Evens A, \*Shah NM, **Fenske TS**, Zelenetz A, Landsburg DL, Howlett C, Mato A, Tsai JP, Reddy N, Handler C, Flowers CR, Cohen JB, Blum K, Song K, Sun H, Press O, Cassaday R, Li S, Jaso J, Medeiros LJ, Sohani AR, Abramson JS. Impact of induction regimen and stem cell transplantation on outcomes in patients with double hit lymphoma: a large multicenter retrospective analysis. *Blood* 124(15): 2354-61, 2014.
32. \*Dhawal B, D'Souza A, Arce-Lara C, Pasquini M, Saber W, Falvo F, Esselman J, Zellner K, **Fenske T**, Hari PN, Hamadani M. Superior efficacy but higher cost of plerixafor and abbreviated-course G-CSF for mobilizing hematopoietic progenitor cells (HPC) in AL amyloidosis. *Bone Marrow Transplantation* 50(4): 610-12, 2015.
33. \*Singavi A, \*Graff T, Schmidt W, Eastwood D, Drobyski W, Horowitz M, Palmer J, Pasquini M, Rizzo D, Saber W, Hari P, **Fenske TS**. Safety of outpatient autologous hematopoietic cell transplantation (AuHCT) for multiple myeloma and lymphoma. *Bone Marrow Transplantation* 50(7): 947-53, 2015.
34. \*Cornell RF, Zhong X, Arce Lara C, Atallah E, Blust L, Drobyski WR, **Fenske TS**, Pasquini MC, Rizzo JD, Saber W, Hari P. Bortezomib-based induction for transplant ineligible AL amyloidosis and feasibility of later transplantation. *Bone Marrow Transplantation* 50(7): 914-7, 2015.
35. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Abramson JS, Petrich AM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Fabregas JC, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL): characteristics, outcomes, and prognostication among a large multicenter cohort. *American Journal of Hematology* 90(9): 778-83, 2015.
36. **Fenske TS**, \*Shah N, Kim K, Saha S, Zhang C, Baim AE, Farnen JP, Onitilo A, Blank JH, Harish A, Wassenaar T, Qamar R, Mansky P, Traynor AM, Mattison RJ, Kahl BS. Weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network phase II study. *Cancer* 121(19): 3465-71, 2015.
37. Satwani P, Ahn KW, Carreras J, Abdel-Aziz A, Cairo MS, Cashen A, Chen AI, Cohen JB, Costa LJ,

- Dandoy C, **Fenske TS**, Freytes CO, Ganguly S, Gale RP, Ghosh N, Hertzberg MS, Hayashi RJ, Kamble RT, Kanate AS, Keating A, Kharfan-Dabaja MA, Lazarus HM, Marks DI, Nishihori T, Olsson RF, Prestidge TD, Rolon JM, Savani BN, Vose JM, Wood WA, Inwards DI, Bachanova V, Maloney DG, Sureda A, Smith S, Hamadani M. A prognostic model predicting autologous transplantation outcomes in children, adolescents and young adults with Hodgkin lymphoma. *Bone Marrow Transplantation* 50(11): 1416-23, 2015.
38. \*Chandran R, Gardiner SK, **Fenske TS**, Spurgeon ES. Survival trends in T-cell prolymphocytic leukemia: A SEER database analysis. *Leukemia & Lymphoma* 57(4): 942-4, 2016.
39. Landsburg D, Petrich A, Abramson J, Sohani A, Press O, Cassaday R, Chavez J, Song K, Zelenetz A, Gandhi M, \*Shah N, **Fenske T**, Jaso J, Medeiros L, Yang D, Nabhan C. Impact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma. *Cancer* 122(4): 559-64, 2016.
40. Kanate AS, Musetti A, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Beitinjaneh A, Chhabra S, **Fenske TS**, Freytes C, Gale RP, Ganguly S, Hertzberg M, Klyuchnikov E, Lazarus HM, Olsson R, Perales MA, Rezvani A, Riches M, Saad A, Slavin S, Smith SM, Sureda A, Yared J, Ciurea S, Armand P, Salit R, Bolanos-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched unrelated donors. *Blood* 127(7): 938-47, 2016.
41. Alinari L, Gru A, Quinion C, Huang Y, Lozanski G, Poston J, Venkataramn G, Oak E, Kreisel F, Park SI, Matthews S, Abramson JS, Lim HI, Martin P, Cohen JB, Evens A, Al-Mansour Z, \*Singavi A, **Fenske TS**, Blum KA. De novo CD5+ diffuse large B-cell lymphoma: adverse outcomes with and without stem cell transplantation in a large, multi-center, rituximab treated cohort. *American Journal of Hematology* 91(4): 395-9, 2016.
42. **Fenske TS**, Ahn KW, \*Graff TM, Digilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda S, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplant. *British Journal of Haematology*, 174(2): 235-48, 2016.
43. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, **Fenske T**, Longo W, Devine SM, Nadamane A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced intensity conditioning with fludarabine, cyclophosphamide, and high dose Rituxan for allogeneic hematopoietic cell transplantation for follicular lymphoma: A phase II multicenter trial from the Blood and Marrow Transplant Network (BMT CTN). *Biology of Blood and Marrow Transplantation*, 22(8): 1440-8, 2016.
44. \*Dhokal B, D'Souza A, Pasquini M, Saber W, **Fenske TS**, Drobyski W, Moss R, Hari P, Abidi M. DAS181 treatment of severe parainfluenza virus 3 pneumonia in allogeneic hematopoietic stem cell transplant recipients requiring mechanical ventilation. *Case Reports in Medicine* 2016 Jan 28 [Epub].
45. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, **Fenske TS**, Ganguly S, Kharfan-Dabaja MA, Prestige TD, Savani BN, Smith SM, Sureda A, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolanos-Meade J, Hamadani M. Reduced-intensity transplantation for lymphomas using haploidentical related donors versus HLA-matched sibling donors. *Journal of Clinical Oncology* 34(26): 3141-9, 2016.
46. \*Dhokal B, Westfall V, **Fenske TS**, Eastwood D, Craig MD, Cumpston A, Shillingburg A, Watkins K, Pasquini MC, D'Souza AD, Atallah E, Hari P, Kanate AS, Hamadani M. Hematopoietic progenitor cell mobilization with ICE chemotherapy versus plerixafor-based strategies in patients with Hodgkin and non-Hodgkin lymphoma. *Biology of Blood and Marrow Transplantation* 22(10): 1773-80, 2016.
47. \*Epperla N, \*Kapke JT, \*Shah N, Hamadani M, Richardson K, Carrum G, Hari PN, \*Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma following autologous hematopoietic cell transplantation. *Clinical Lymphoma, Myeloma & Leukemia* 16(23): 672-678, 2016.
48. \*Raj RV, Hari P, Pasquini M, \*Epperla N, D'Souza A, **Fenske T**, Shaw BE, Rizzo D, Drobyski W, Hamadani M. Impact of haploidentical hematopoietic cell transplantation conditioning intensity on the incidence and severity of post-transplantation viral infections. *Bone Marrow Transplantation* 51(12): 1602-04, 2016.
49. \*Epperla N, Costa LJ, Maddocks K, Reddy NM, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Chavez J, Calzada O, Lansigan F, Nasheed H, Barta S, Zhou Z, Jaglal M, Chhabra S, Hernandez-Ilizaliturri FJ, Xavier AC, Mehta A, Pekar D, Forero-Torres A, Al-Mansour Z, Evens AM, Cohen JB, Flowers CR, **Fenske TS**, Hamadani M. Diffuse large B-cell lymphoma with primary treatment failure:

- ultra-high risk features and benchmarking for experimental therapies. *American Journal of Hematology* 92(2): 161-170, 2017.
50. Chen RW, Li H, Bernstein SH, Kawash S, Rimsza LM, Forman SJ, Constine L, Shea TC, Cashen AF, Blum KA, **Fenske TS**, Barr PM, Phillips T, Leblanc M, Fisher RI, Cheson BD, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. RB but not R-HCVAD is a feasible induction regimen prior to auto-HCT in frontline MCL: results of SWOG study S1106. *British Journal of Haematology* 176(5):759-769, 2017.
  51. Hamadani M, Kanate AS, DiGilio A, Ahn KW, Smith SM, Lee, JW, Ayala E, Chao N, Hari P, Bolanos-Meade, J, Gress R, Anderson NS, Chen YB, Farooq U, Schiller G, Yared J, Sureda A, **Fenske TS**, Olteanu H. Allogeneic hematopoietic cell transplantation for aggressive NK-cell leukemia: a CIBMTR analysis. *Biology of Blood and Marrow Transplantation* 23(5): 853-56, 2017.
  52. \*Epperla N, Hamadani H, Cashen AF, Ahn KW, Oak E, Kanate AS, Calzada O, Cohen JB, Farmer L, Ghosh N, Tallarico M, Nabban C, Costa LJ, Kenkre VP, Hari PN, **Fenske TS**. Predictive factors and outcomes for ibrutinib therapy in relapsed / refractory mantle cell lymphoma - a "real world" study. *Hematological Oncology* 2017 Jan 8 [Epub ahead of print].
  53. \*Epperla N, Dhakal B, **Fenske TS**, Ramalingam S, Shuff J, Hosking P, Rein L, Banerjee A, Hari P, D'Souza A, Shah N, Siker M, Erickson-Wittmann BA, Hamadani M. Local disease control in ocular adnexal lymphoproliferative disorders: comparative outcomes of MALT versus non-MALT histologies. *Clinical Lymphoma Myeloma and Leukemia* 2017 Feb 16 [Epub ahead of print].
  54. Kanate AS, Hari PN, Pasquini MC, Visotcky A, Ahn KW, Boyd J, \*Guru Murthy GS, Rizzo JD, Saber W, Drobyski W, Michaelis L, Atallah E, Carlson KS, D'Souza A, **Fenske TS**, Cumpston A, Bunner P, Craig M, Horowitz MM, Hamadani M. Recipient immune modulation with atorvastatin for acute graft-versus-host disease prophylaxis following allogeneic transplantation. *Biology of Blood and Marrow Transplantation* (in press). 2017 April 12 [Epub ahead of print].
  55. Haverkos BM, Abbott D, Hamadani M, Armande P, Flowers C, Merryman RW, Kamdar M, Kanate AS, Saad A, Mehta M, Ganguly S, **Fenske TS**, Hari P, Lowsky R, Andritsos L, Jagasia M, Bashey A, Brown S, Bachanova V, Stephens D, Mineishi S, Nakamura R, Chen YB, Blazar BR, Gutman J, Devine SM. PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVDH. *Blood* 2017 May 03 [Epub ahead of print].
  56. Landsburg DJ, Falkiewicz, MK, Maly J, Blum KA, Howlett C, Feldman T, Mato AR, Hill BT, Li S, Medeiros LJ, Torka P, Hernandez-Iliazlitzurri F, Reddy NM, \*Singavi A, **Fenske TS**, Chavez JC, Kaplan JB, Behdad A, Petrich AM, Bast MA, Vose JM, Olszewski AJ, Costa C, Lansigan F, Gerson JN, Barta SK, Calzada O, Cohen JB, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Nathan S, Cassaday RD. Outcomes of double hit lymphoma patients who achieve first complete remission. *Journal of Clinical Oncology* 2017 May 05 [Epub ahead of print].
  57. \*Kapke JT, \*Epperla N, \*Shah N, Richardson K, Carrum G, Hari PN, Pingali SR, Hamadani M, Karmali R, **Fenske TS**. The impact of routine surveillance imaging on the outcomes of patients with classical Hodgkin lymphoma following autologous hematopoietic cell transplantation. *Clinical Lymphoma Myeloma and Leukemia* (in press).
  58. \*Epperla N, Maddocks KJ, Salhab M, Chavez JC, Reddy N, Karmali R, Umyarova E, Bachanova V, Costa C, Glenn M, Calzada O, Xavier AC, Zhou Z, Hossain NM, Hernandez-Iliazlitzurri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Flowers CR, Cohen JB, **Fenske TS**, Hamadani M, Costa L. C-MYC+ relapsed and refractory diffuse large B-cell lymphoma: impact of additional "hits" and outcomes with subsequent therapy. *Cancer* (in press).
  59. Casulo C, Friedberg JW, Ahn KW, Flowers C, DiGilio A, Smith SM, Ahmed S, Inwards D, Aljurf M, Chen AI, Choe H, Cohen J, Copelan E, Farooq U, **Fenske TS**, Freytes C, Gaballa S, Ganguly S, Jethava YS, Kamble RT, Kenkre VP, Lazarus H, Lazaryan A, Olsson RF, Rezvani AR, Rizzieri D, Seo S, Shah GL, Shah N, Sohl M, Sureda A, William B, Cumpston A, Zelenetz A, Link BK, Hamadani M. Autologous transplantation improves survival in patients with follicular lymphoma experiencing early therapy failure after frontline chemoimmunotherapy: A NLCS and CIBMTR analysis. Submitted.
  60. \*Epperla N, Calzada O, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Deferred treatment is a safe and viable option for selected patients with mantle cell lymphoma. Submitted.
  61. \*Epperla E, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani A, Smith SM, Sureda A, **Fenske TS**, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing Reduced Intensity Conditioning Reduces the Risk of Therapy Failure following Allogeneic Transplantation in B-cell NHL: A CIBMTR Analysis. Submitted.

62. \*Epperla N, Greenwell B, Staton AS, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon MJ, Danilov AV, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Complex karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. In preparation.
63. Levin A, Kleman A, Rein L, Tarima S, Michaelis LC, Carlson KC, Hamadani M, **Fenske TS**, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute myelogenous leukemia treated in teaching versus non-teaching hospitals: a large database analysis. In preparation.
64. \*Epperla N, Hamadani M, **Fenske TS**, Costa LJ. Incidence and survival trends in mantle cell lymphoma. *British Journal of Haematology* 2017 April 25 [Epub ahead of print].
65. Burris HA, Flinn IW, Patel MR, **Fenske TS**, Deng C, Brander DM, Gutierrez M, Essell JH, Savona MR, Kuhn JG, Miskin HP, Sportelli P, Weiss MS, Vakkalanka S, O'Connor OA. TGR-1202, a novel, once-daily PI3K??inhibitor, in relapsed or refractory chronic lymphocytic leukemia and B-cell lymphoma. Submitted.
66. \*Epperla E, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani A, Smith SM, Sureda A, **Fenske TS**, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing Reduced Intensity Conditioning Reduces the Risk of Therapy Failure following Allogeneic Transplantation in B-cell NHL: A CIBMTR Analysis. Submitted.
67. Kanate AS, DiGilio A, Ahn KW, Monzr AM, Jacobsen E, Steinberg A, Hamerschlak N, Kharfan-Dabaja M, Salit R, Ball E, Bashir Q, Cashen A, Couriel D, Diez-Martin J, Katsanis E, Linhares Y, Mori S, Nash R, Pawarode A, Perales MA, Phipps CD, Richman C, Savani BN, Shapira MY, Stiff P, Strair R, **Fenske TS**, Smith SM, Sureda A, Olteanu H, Hamadani M. Allogeneic Hematopoietic Cell Transplantation for Extranodal Natural Killer/T-cell Lymphoma, Nasal Type: A CIBMTR Analysis. Submitted.
68. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske TS**, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumedil A, Hamadani M, Pasquini M. Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed Follicular Lymphoma. A Combined Analysis on Behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR. Submitted.
69. \*Epperla N, Greenwell B, Staton AS, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon MJ, Danilov AV, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Complex karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. In preparation.
70. Dabaja-Kharfan MA, Kumar A, Ayala E, Hamadani M, . . . **Fenske TS** . . . Carpenter P, Savani BN. Practice recommendations on indication and timing of hematopoietic cell transplantation in mature T-cell lymphomas on behalf of the guidelines committee of the American Society for Blood and Marrow Transplantation. In preparation.
71. \*Thompson J, Yin Z, D'Souza A, **Fenske T**, Hamadani M, Hari P, Rizzo D, Pasquini M, Saber W, Shah N, Shaw BE, Shahir K, Banerjee A, Drobycki WR. Etanercept and corticosteroid therapy for the treatment of late-onset idiopathic pneumonia syndrome. *Biology of Blood and Marrow Transplantation* 23(11): 1955-60, 2017.
72. Pilchowska M, Pittaluga S, Ferry JA, Hemminger J, Chang H, Kanakry JA, Sehn LH, Feldman T, Abramson JS, Kritharis A, Hernandez-Ilizaliturri FJ, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gupta GK, Gascoyne RD, Jaffe ES, Evens AM. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. *Blood Advances* 1(26): 2600-09, 2017.
73. \*Epperla N, Ahn KW, Armande P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, **Fenske TS**, Sureda A, Smith S, Hamadani M. Fludarabine and busulfan versus fludarabine, cyclophosphamide and rituximab as reduced-intensity conditioning for allogeneic transplantation in follicular lymphoma. *Biology of Blood and Marrow Transplantation* 24(1): 78-85, 2018.
74. Shah NN, Szabo A, Huntington S, Epperla N, Reddy N, Ganguly S, Vose J, Obiozor C, Faruqi F, Kovach A, Costa LJ, Xavier A, Okal R, Kanate A, Ghosh N, Kharfan-Dabaja M, Strelec L, Hamadani M, **Fenske TS**, Calzada O, Cohen J, Chavez J, Svoboda J. R-CHOP vs. dose-adjusted R-EPOCH for frontline management of primary mediastinal B-cell lymphoma: a multi-center analysis. *British Journal of Haematology* 180(4): 534-44, 2018.
75. Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Picardi IA, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ, Bartlett NL, Walewski J, Chen R, Ramchandren R, Zinzani PL, Cunningham D, Rosta A, Josephson NC, Song E, Sachs J, Liu R, Jolin HA, Huebner D, Radford J. Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin's

- lymphoma. *New England Journal of Medicine* 378(4): 331-344, 2018. [Listed as a “participating investigator” but not as an author].
76. Kharfan-Dabaja MA, Raj R, Nikolaenko L, Ahmed S, Reddy N, Nathan S, Cherry M, El-Jurdi N, Obiozor C, **Fenske TS**, Song J, Muzzafar T, Ayala E, Savani B, Khawandanah M, Caimi P, Hamadani M, Forman SJ, Hussaini M, de Lima M, Olteanu H, Al Malki M, Shah B, Chavez J, Kumar A, Ganguly S. Efficacy of high-dose therapy and autologous HCT in gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: a US multicenter collaborative study. *Biology of Blood and Marrow Transplantation* 24(3): 486-493, 2018.
  77. Drobyski WR, Szabo A, Zhu F, Keever-Taylor C, Hebert KM, Dunn R, Yim S, Johnson B, D’Souza A, Eapen M, **Fenske TS**, Hari P, Hamadani M, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw B, Pasquini M. Tocilizumab, tacrolimus and methotrexate for the prevention of acute GVHD: low incidence of lower GI tract disease. *Haematologica* 103(4): 717-727, 2018.
  78. Shah N, Ahn KW, Litovich C, **Fenske TS**, Ahmed S, Battiwalla M, Benjanyan N, Dahi PB, Bonaos-Meade J, Chen A, Ciurea S, Bachanova V, DeFilipp Z, Epperla N, Farhadfar N, Herrera A, Haverkos B, Holmberg L, Hossain N, Kharfan-Dabaja MA, Kenkre VP, Lazarus HM, Murthy HS, Nishihori T, Rezvani AR, D’Souza A, Savani BN, Ulrickson M, Waller EK, Sureda A, Smith S, Hamadani M. Outcomes of Medicare-age eligible NHL patients receiving RIC allogeneic transplantation: a CIBMTR analysis. *Blood Advances* 2(8): 933-940, 2018.
  79. Greenwell BI, Staton AD, Lee MJ, Switchenko JM, Saxe D, Maly JJ, Blum KA, Grover NS, Mathews S, Gordon MJ, Danilov AV, \*Epperla N, **Fenske TS**, Hamadani M, Park SI, Flowers CR, Cohen JB. Complex karyotype in mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. *Cancer* 124(11): 2306-2315, 2018.
  80. \*Epperla E, Hamadani M, Ahn KW, He F, Kodali D, Kleman A, Hari PN, Pasquini M, **Fenske TS**, Craig MD, Kanate AS, Bachanova V. Survival of lymphoma patients experiencing relapse or progression after allogeneic hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 24(5): 983-988, 2018.
  81. Raj RV, Hamadani M, Szabo A, Pasquini MC, Shah NN, Shaw BE, Saber W, Rizzo JD, Jerkins J, **Fenske TS**, D’Souza A, Dhakal B, Zhang C, Konings S, Hari PN, Chhabra S. Peripheral blood grafts for T-cell replete haploidentical transplantation increase the incidence and severity of cytokine release syndrome. *Biology of Blood and Marrow Transplantation* 24(8): 1664-1670, 2018.
  82. \*Badar T, Hari P, Chhabra S, Dhakal B, Drobyski W, **Fenske TS**, Hamadani M, Pasquini M, Rizzo D, Saber W, Shah N, Shaw B, D’Souza A. Use of propylene glycol-free melphalan conditioning in light chain amyloidosis undergoing autologous hematopoietic cell transplantation is associated with significantly lower hospitalization days. *Bone Marrow Transplantation* 53(9): 1210-12013, 2018.
  83. Aqeel M, Uysal-Biggs N, **Fenske TS**, Rao N. One pulmonary lesion, 2 synchronous malignancies. *J Investig Med High Impact Case Rep* 2018 Jun 28.
  84. Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romera PL, Eradat H, Scarisbrick J, Tsianaka A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierra MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M. Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomized, controlled phase 3 trial. *Lancet Oncology* 19(9): 1192-1204, 2018. [Listed as a “participating investigator” but not as an author].
  85. Voshtina E, Szabo A, Hamadani H, **Fenske TS**, D’Souza A, Chhabra S, Saber W, Drobyski WR, Hari H, Shah NN. Impact of obesity on outcomes of elderly patients undergoing allogeneic hematopoietic cell transplant for myeloid malignancies. *Biology of Blood and Marrow Transplantation* 25(1): e33-e38, 2019.
  86. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros J, Wang M, Cohen JB, Calzada O, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose MJ, Bast M, **Fenske TS**, Narayana S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan AM, Wagner-Johnson N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amengual JE, Lue JK, Diefenback C, Fisher RI, Barta SK. Survival outcomes of younger patients with mantle cell lymphoma treated in the rituximab era. *Journal of Clinical Oncology* 37(6): 471-480, 2019.
  87. Shah NN, Szabo A, Saba R, Strelec L, Kodali D, Vaughn J, Esan O, Yang DT, Mato AR, Kanate AS, Olteanu H, Hamadani M, **Fenske TS**, Kenkre VP, Svoboda J, Cashen AF, Epperla N. Multicenter



- analysis of advanced stage grade 3A follicular lymphoma outcomes by frontline treatment regimen. *Clinical Lymphoma, Myeloma and Leukemia* 19(2): 95-102, 2019.
88. \*Badar T, Hamadani M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier AC, Karmali R, Salhab M, Reddy N, Hernandez-Ilizaliturri FJ, Flowers C, Evens AM, Zhou Z, Lansigan F, Barta SK, Cohen JB, **Fenske TS**, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B-cell lymphoma with primary treatment failure according to putative cell of origin. *Leukemia & Lymphoma* 60(4): 940-946, 2019
89. Guru Murthy GS, Hari PN, Szabo A, Pasquini M, Narra R, Khan M, Abedin S, Chhabra S, Dhakal B, D'Souza A, Drobyski WR, Rizzo JD, Runass L, Shah NN, Shaw B, Saber W, **Fenske TS**, Hamadani M. Outcomes of reduced intensity conditioning allogeneic hematopoietic cell transplantation performed in the inpatient versus outpatient setting. *Biology of Blood and Marrow Transplantation* 25(4): 827-833, 2019.
90. Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, **Fenske TS**, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: A CIBMTR analysis. *Journal of Hematology and Oncology* 12(1):6, 2019.
91. Epperla N, \*Badar T, Szabo A, Vaughn J, Borson S, Saini N, Patel RD, Shah NN, Hamadani M, Ahmed S, Cashen A, **Fenske TS**. Post-relapse survival in diffuse large B-cell lymphoma patients after experiencing therapy failure following autologous hematopoietic cell transplantation. *Blood Advances* 3(11): 1661-69, 2019.
92. Dhakal B, Giri S, \*Levin A, Rein L, **Fenske TS**, Chhabra S, Shah N, Szabo A, D'Souza AD, Pasquini M, Hari P and Hamadani M. Unplanned 30-day readmissions after hematopoietic cell transplantation in the U.S. *JAMA Network Open* 2(7): e196476, 2019.
93. Kanate AS, Kumar A, Dreger P, Dreyling M, LeGouill S, Corradini P, Bredeson C, **Fenske TS**, Smith S, Sureda A, Moskowitz A, Friedberg J, Inwards D, Herrera A, Kharfan-Dabaja M, Reddy N, Montoto S, Robinson S, Abutalib S, Gisselbrecht C, Vose J, Gopal A, Shadman M, Perales M, Carpenter P, Savani B, Hamadani M. Maintenance therapies for Hodgkin and non-Hodgkin lymphomas after autologous transplantation: a consensus project of ASBMT, CIBMTR and LWP-EBMT. *JAMA Oncology* 5(5): 715-22, 2019.
94. Ahmed S, Kanakry JA, Ahn KW, Litovich C, Abdel-Azim H, Aljurf M, Bacher VU, Bejanyan N, Cohen JB, Farooq U, Fuchs EJ, Bolaños-Meade J, Ghosh N, Herrera AF, Hossain NM, Inwards D, Kanate AS, Martino R, Munshi PN, Murthy H, Mussetti A, Nieto Y, Perales MA, Romee R, Savani BN, Seo S, Wirk B, Yared JA, Sureda A, **Fenske TS**, Hamadani M. Lower Incidence of Chronic GVHD and Relapse in Post-transplant Cyclophosphamide-based Haploidentical Transplantation Versus Matched Sibling Donor Reduced Intensity Conditioning Transplantation for Hodgkin Lymphoma. *Biology of Blood and Marrow Transplantation* 25(9): 1859-68, 2019.
95. \*Badar T, Khan MA, Szabo A, Chhabra S, Dhakal B, **Fenske TS**, Hamadani M, Hari P, Jerkins J, Shah N, Shaw B, D'Souza A. Incidence and characteristics of engraftment syndrome after autologous hematopoietic cell transplantation in light chain amyloidosis. *Amyloid* 26(4): 210-15, 2019.
96. Guru Murthy GS, Szabo A, Hamadani M, **Fenske TS**, Shah NN. Contemporary outcomes for advanced stage classical Hodgkin lymphoma in the United States – analysis of the Surveillance Epidemiology and End Results Database. *The Oncologist* 24(11): 1488-95, 2019.
97. Kamdar M, Li H, Chen RW, Rimsza LM, Leblanc ML, **Fenske TS**, Barr P, Phillips TJ, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-Year Outcomes of SWOG S1106: A Randomized Phase II US Intergroup Study of R-HCVAD Vs. R-Bendamustine followed by autologous stem cell transplant for patients with mantle cell lymphoma. *Blood Advances* 3(20): 3132-35, 2019.
98. \*Badar T, Epperla N, Szabo A, Borson S, Vaughn J, \*George G, Saini N, Patel RD, Ahmed S, Shah NN, Cashen A, Hamadani M, **Fenske TS**. Trends in post-relapse survival in classical Hodgkin lymphoma patients after experiencing therapy failure following autologous hematopoietic cell transplantation. *Blood Advances* 4(1): 47-54, 2020.
99. Shah NN, Johnson B, **Fenske TS**, Raj RV, Hari PH. Intrathecal chemotherapy for steroid-refractory CAR-T associated neurotoxicity. *Blood Advances* 4(10): 2119-22, 2020.
100. Chhabra S, Narra RK, Wu R, Szabo A, George G, Michaelis LC, D'Souza A, Dhakal B, Drobyski WR, **Fenske TS**, Jerkins JH, Pasquini MC, Rizzo RD, Saber W, Shah NN, Shaw BE, Hamadani M, Hari

- PN. Fludarabine/busulfan conditioning based allogeneic hematopoietic cell transplantation for myelofibrosis: role of ruxolitinib in improving survival outcomes. *Biology of Blood and Marrow Transplantation* 26(5): 893-901, 2020.
101. Jagadeesh D, Majhail N, He Y, Ahn KW, Litovich C, Ahmed S, Aljurf M, Bacher U, Badawy SM, Bejanyan N, Cairo M, Cerny J, Epperla N, Farhadfar N, Freytes CO, Gale RP, Haverkos B, Hossain N, Inwards D, Kamble RT, Kenkre VP, Lazarus HM, Lazaryan A, Lekakis L, Mei M, Murthy HS, Mussetti A, Nathan S, Nishihori T, Olsson RF, Ramakrishnan GP, Savani BN, Yared JA, **Fenske TS**, Kharfan-Dabaja MA, Sureda A, Hamadani M. Outcomes of Rituximab-BEAM versus BEAM conditioning in patients with diffuse large B-cell lymphoma undergoing autologous transplantation. *Cancer* 126(10): 2279-87, 2020.
  102. Diefenbach CS, Hong F, Ambinder RF, Cohen JB, Robertson MJ, David KA, Advani RH, **Fenske TS**, Barta SK, Palmisiano ND, Svoboda J, Morgan DS, Karmali R, Kahl BS, Ansell SM. Safety and efficacy ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: a phase 1 trial of the ECOG-ACRIN research group (E4412). *Lancet Haematology* 7(9):e660-670, 2020.
  103. Hamadani M, Khanal M, Ahn KW, Litovich C, Chow VA, Eghtedar A, Karmali R, Winter A, **Fenske TS**, Sauter C, Kharfan-Dabaja MA, Awan FT. Higher total body irradiation dose-intensity in fludarabine/TBI-based reduced-intensity conditioning regimen is associated with inferior survival in non-Hodgkin lymphoma patients undergoing allogeneic transplantation: Flu/2Gy TBI vs Flu/4Gy TBI in NHL. *Biol Blood Marrow Transplant* 26(6): 1099-1105, 2020.
  104. Chhabra S, Visotcky A, Pasquini MC, Zhu F, Tang X, Zhang MJ, Thompson R, Abedin S, D'Souza A, Dhakal B, Drobyski WR, **Fenske TS**, Jerkins JH, Douglas Rizzo J, Runaas L, Saber W, Shah NN, Shaw BE, Horowitz MM, Hari PN, Hamadani M. Ixazomib for Chronic Graft-versus-Host Disease Prophylaxis following Allogeneic Hematopoietic Cell Transplantation. *Biol Blood Marrow Transplant* 26(10): 1876-85, 2020.
  105. Ahmed S, Ghosh N, Ahn KW, Khanal M, Litovich C, Mussetti A, Chhabra S, Cairo M, Mei M, William B, Nathan S, Bejanyan N, Olsson RF, Dahi PB, van der Poel M, Steinberg A, Kanakry J, Cerny J, Farooq U, Seo S, Kharfan-Dabaja MA, Sureda A, **Fenske TS**, Hamadani M. Impact of type of reduced-intensity conditioning regimen on the outcomes of allogeneic haematopoietic cell transplantation in classical Hodgkin lymphoma. *British Journal of Haematology* 190(4): 573-582, 2020.
  106. Shah NN, Johnson B, Scheider D, Zhu F, Szabo A, Keever-Taylor CA, Krueger W, Worden AA, Kadan MJ, Yim S, Cunningham A, Hamadani M, **Fenske TS**, Dropulic B, Orentas R, Hari P. Bi-specific anti-CD19 anti-CD20 CAR T-cells for relapsed and refractory B-cell malignancies. *Nature Medicine* 26(10): 1569-75, 2020.
  107. Epperla N, Ahn KW, Khanal M, Litovich C, Ahmed S, Ghosh N, **Fenske TS**, Kharfan-Dabaja MA, Sureda A, Hamadani M. Impact of reduced-intensity conditioning regimens for allogeneic hematopoietic cell transplantation on outcomes for diffuse large B-cell lymphoma. *Transplant and Cellular Therapy* 27: 58-66, 2021. 106.
  108. Shah NN, Ahn KW, Litovich C, Sauter C, **Fenske TS**, Hamadani M. Is autologous transplantation in relapsed DLBCL patients achieving only a PET/CT positive partial remission appropriate in the CAR T-cell era? *Blood* 137: 1416-23, 2021.
  109. Mato AR, Shah NN, Jurczak W, Chan CY, Pagel JM, Woyach JA, Fakhri B, Eyre TA, Lamanna N, Patel MR, Alencar A, Lech-Maranda E, Wierda WG, Coombs CC, Gerson JN, Ghia P, Le Gouill S, Lewis DJ, Sundaram S, Cohen JB, Flinn IW, Tam CS, Barve MA, Kuss B, Taylor J, Lewis KL, Roeker L, Davids MS, Tan XN, **Fenske TS**, Tsai DE, Ku NC, Zhu E, Chen MS, Yin M, Nair B, Ebata K, Marella N, Brown JR, Wang M. LOXO-305 in relapsed or refractory B-cell malignancies. *Lancet* 397: 892-901, 2021.
  110. Munshi PN, Hamadani M, Kumar A, Dreger P, Friedbert JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill B, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith S, Carlo-Stella C, Savani B, Robinson SP, **Fenske TS**. ASTCT, CIBMTR and EBMT Clinical Practice recommendations for transplant and cellular therapies in mantle cell lymphoma. *Bone Marrow Transplantation* 56(12): 2911-2921, 2021.
  111. Bond, DA, Switchenko JM, Villa D, Maddocks K, Churnetski M, Gerrie AS, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, **Fenske TS**, Malacek M, Kahl BS, Flowers CR, Blum KA, Cohen JB. Early relapse is associated with inferior survival after both intensive and less intensive

- frontline treatment in patients with mantle cell lymphoma. *Blood Advances* . 5(23): 5178-5189, 2021.
112. Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, **Fenske TS**, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma, and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. *British Journal of Haematology* 197(2): 212-222, 2022.
  113. Mohan M, Nagvally S, Shah NN, Michaelis L, Chhabra S, D'Souza A, Abedin S, Runaas L, Guru Murthy GS, Longo W, Ledebner N, Hamadani M, Dhakal B, Hari P, **Fenske TS**. Shorter interval between treatment and COVID immunization is associated with poor seroconversion in patients with hematologic malignancies. *Clinical Lymphoma, Myeloma and Leukemia* 22(7): e495-e497, 2022.
  114. Abid MB, Rubin M, Ledebner N, Szabo A, Longo W, Mohan M, Shah N, **Fenske TS**, Abedin S, Runaas A, D'Souza A, Chhabra S, Dhakal B, Hamadani M. Effectiveness of mRNA-based SARS-CoV-2 vaccine booster among non-seroconverting hematopoietic cell transplantation, CAR T-cell and BiTE recipients. *Cancer Cell* 40(4): 340-342, 2022.
  115. Zurko JC, Johnson BD, Aschenbrenner E, **Fenske TS**, Hamadani M, Hari P, Shah NN. Use of early intrathecal therapy to manage high-grade immune effector cell-associated neurotoxicity syndrome. *JAMA Oncology* 8(5): 773-775, 2022.
  116. Ahmed G, Bhasin-Chhabra B, Szabo A, Shah NN, Longo W, Dhakal B, Chhabra S, D'Souza A, **Fenske TS**, Hamadani M. Impact of chronic kidney disease and acute kidney injury on safety and outcomes of CAR T-cell therapy in lymphoma patients. *Clinical Lymphoma, Myeloma & Leukemia* 22(11): 863-868, 2022.
  117. Zurko JC, **Fenske TS**, Johnson BD, Bucklan D, Schneider D, Szabo A, Xu H, Chaney K, Hamadani M, Hari H, Shah NN. Predictors of response and long-term outcomes for patients treated with bispecific LV20.19 CAR T-cells. *American Journal of Hematology* 97(12): 1580-1588, 2022
  118. Epperla N, Switchenko J, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Hamadani M, **Fenske TS**, Martin P, Guo J, Malecek M, Kahl BS, Flowers CR, Link BK, Kaplan LD, Inwards DJ, Feldman AL, His ED, Maddocks K, Blum KA, Bartlett NL, Cerhan JR, Leonard JP, Habermann TM, Maurer MJ, Cohen JB. Impact of diagnosis to treatment interval in patients with newly diagnosed mantle cell lymphoma. *Blood Advances* 7(11): 2287-2296, 2023.
  119. Furqan F, Maring M, Szabo A, **Fenske TS**, Hamadani M, Shah NN. Salvage Polatuzumab and Allogeneic Transplant Rescues B-cell Lymphoma Patients Failing CAR-T cell Therapy. *Blood Advances* 7(11): 2463-2467, 2023.
  120. Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma SM, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam C, Munir T, Nagai H, Hernandez-Ilizaliturri, Kumar A, **Fenske TS**, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Pirtobrutinib in covalent BTK-inhibitor pre-treated mantle cell lymphoma. *Journal of Clinical Oncology* 41(24): 3988-3997, 2023.
  121. Streck, JM, Lee JW, Walter AW, Rosen RL, Gareen IF, Kircher SM, Herman BA, Carlos RC, Kumar S, Mayer IA, Saba NF, **Fenske TS**, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempny C, Shanafelt TD, Wagner LI, Land SR, Park ER, Ostroff JS. Cigarette and alternative tobacco product use among adult cancer survivors enrolled in 9 ECOG-ACRIN clinical trials. *Cancer, Epidemiology, Biomarkers & Prevention* 32(11): 1552-1557, 2023.
  122. Gerson JN, Handorf E, Villa D, Gerrie AS, Chapani P, Li S, Medeiros J, Wang M, Cohen JB, Calzada O, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, **Fenske TS**, Narayana Rao Gari S, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Burns T, Donovan AM, Wagner-Johnston N, Messmer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Pulluri B, Amendual JE, Lue JK, Diefenbach C, Fisher RI, Barta SK. Outcomes of patient with blastoid and pleomorphic variant mantle cell lymphoma after first-line rituximab-based chemotherapy. *Blood Advances* 7(24): 7393-7401, 2023.
  123. Fehniger TA, Watkins MP, Ezenwajiaku N, Wan F, Hurd DD, Cashen AF, Blum KA, Goy A, **Fenske TS**, Wagner-Johnston ND, Carson K, Siegel MJ, Russler-Germain D, Schneider SE, Mehta-Shah N, Kahl B, Bartlett NL. A phase 2 study of interrupted and continuous dose lenalidomide in relapsed/refractory classical Hodgkin lymphoma. *Haematologica* [14 Sept 2023 Epub ahead of print]
  124. Walter AW, Lee JW, Streck JM, Gareen IF, Kircher SM, Herman BA, Carlos RC, Kumar SK, Mayer I,

- Saba NF, **Fenske TS**, Neal JW, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shanafelt TD, Wagner LI, Land SR, Ostroff JS, Park ER. The effect of neighborhood socioeconomic disadvantage on smoking status, quit attempts, and receipt of cessation support among adults with cancer: results from 9 ACOG-ACRIN Cancer Research Group (EA) trials. *Cancer* [05 Oct 2023 Epub ahead of print]
125. \*Rezazadeh A, Szabo A, \*Monahan K, Kurana A, Inwards DJ, Lunning MA, Cashen A, Bartlett NL, Caimi PF, Rodgers TD, Barr PM, Chowdhury SM, Epperla N, Mendries H, Hill BT, Oh TS, Karmali R, Chang JE, Goyal G, Parsons BM, Isaac KM, Portell CA, Siker M, King DM, **Fenske TS**. Outcomes of primary bone diffuse large B-cell lymphoma in the rituximab era: a multi-center retrospective analysis. *Haematologica* [19 Oct 2023 Epub ahead of print]
126. Kahl BS, Jegede Y, Peterson C, Swinnen LJ, Habermann TM, Schuster SJ, Weiss M, Fishkin PA, Ehmann C, **Fenske TS**, Williams ME. Long term follow up of the RESORT study (E4402): a randomized phase III comparison of two different rituximab dosing strategies for low tumor burden follicular lymphoma. *Journal of Clinical Oncology* [9 Jan 2024 Epub ahead of print].
127. Karmali R, Galvez C, Hamadani M, Gordon LI, Winter JN, Ma S, Nelson V, **Fenske TS**, Shah NN, Jagadeesh D, Klein AK, Helenowski I, Chen R, Mi X, Petrich A, Evens AM, Pro B. A phase I-II trial of DA-EPOCH-R plus ixazomib for MYC-aberrant lymphoid malignancies: the DACIPHOR regimen. *Blood Advances* [18 Jan 2024 Epub ahead of print].
128. Malarkannan S, Kearl T, Wang D, Burns, Johnson B, Mei A, Rao S, Schneider D, Astle JM, **Fenske T**, Hamadani M, Astle JM, Hari P, Shah NN. Genetic and immunological predispositions to bispecific anti-CD19/CD20 CAR T cell therapy. Submitted.

### **Books, Chapters, and Reviews**

1. **Fenske TS**, Bartlett NL. "Lymphoma of the Mediastinum," in Pearson's Thoracic and Esophageal Surgery, 3rd edition, Patterson GA, Pearson FG, Cooper JD, Deslauriers J, Rice TW, Luketich JD, Lerut A (editors), 2008.
2. \*Singavi A, Harrington A, **Fenske TS**. "Post Transplant Lymphoproliferative Disorders," in Cancer Treatment and Research: Non-Hodgkin Lymphoma. Evens A, Blum K (editors), Volume 165, pp 305-327, 2014.
3. \*Pingali SR, **Fenske TS**. "Hematopoietic Cell Transplantation in Mantle Cell Lymphoma." In Hematopoietic Cell Transplants: Concepts, Controversies and Future Directions, Lazarus H, Gale RP, Keating A, Bacigalupo A, Munker R, Atkinson K, and Abutalib SA (editors), 2016. In press.
4. \*Epperla N, **Fenske TS**. "Hematopoietic Cell Transplantation in Mantle Cell Lymphoma" In Blood & Bone Marrow Transplantation: Expert Clinical Manual, Abutalib SA and Hari P (editors), 2017. In press.
5. \*Kapke JT and **Fenske TS**. "Aggressive Lymphomas" in Concise Guide to Hematology, Lazarus H and Schmaier AH (editors), 2017. In preparation.
6. **Fenske TS**, Pengue G, Graubert TA. Dominant negative effects of the AML1/ETO fusion oncoprotein. *Cell Cycle* 4(1): 33-36, 2005.
7. \*Hake CR, Graubert TA, **Fenske TS**. Does autologous transplantation directly increase the risk of secondary leukemia in lymphoma patients? *Bone Marrow Transplantation* 39(2): 59-70, 2007.
8. \*Maramattom LV, **Fenske TS**. "Aggressive B-cell Non-Hodgkin Lymphoma," in Hospital Physician Hematology Board Review Manual (August 2011), Jacobsen ED (editor).
9. \*Cornell RF, **Fenske TS**. "Indolent B-cell Non-Hodgkin Lymphoma," in Hospital Physician Hematology Board Review Manual (October 2011), Jacobsen ED (editor).
10. Sehn LH, **Fenske TS**, Laport GG. Follicular lymphoma: Prognostic factors, conventional therapies, and hematopoietic cell transplantation. *Biology of Blood and Marrow Transplantation* 18 (1) (Supplement): S82-S91, 2012.
11. \*Pingali SR, **Fenske TS**. "Limited-stage Hodgkin lymphoma," in Hospital Physician Hematology Board Review Manual. (August 2012), Jacobsen ED (editor).
12. \*Randhawa J, \*Pingali SR, **Fenske TS**. "Advanced-stage and relapsed/refractory Hodgkin lymphoma," in Hospital Physician Hematology Board Review Manual. (October 2012), Jacobsen ED (editor).
13. Klyuchnikov E, Bacher U, \*Kroll T, Shea TC, Lazarus H, Bredeson C, **Fenske TS**. Allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma: who, when and how? *Bone Marrow Transplantation*, 49(1): 1-7, 2014.
14. \*Shah N, **Fenske TS**. Post-transplant lymphoproliferative disorders," in Hospital Physician Hematology Board Review Manual. (June 2013), Litchkofski, R (editor).
15. **Fenske TS**. Why is stem cell transplantation so underused in follicular lymphoma? *ASCO Post*, Volume 4,

Issue 12 (July 25, 2013).

16. \*Epperla N, **Fenske TS**, Hari PN, Hamadani M. Recent advances in post autologous transplantation maintenance therapies in B-cell non-Hodgkin lymphomas. *World Journal of Transplantation* 5(3): 81-88, 2015.
17. \*Epperla N, **Fenske TS**, Lazarus HM, Hamadani M. Post autologous transplant maintenance therapies in lymphoid malignancies: are we there yet? *Bone Marrow Transplantation*, 50(11): 1393-404, 2015.
18. **Fenske TS**, Bredeson C, Hamadani M, Cohen JB, Costa LJ, Kahl B, Evens AM, Hamlin PA, Lazarus HM, Petersdorf E. Allogeneic hematopoietic cell transplantation as curative therapy for patients with non-Hodgkin lymphoma: increasingly successful application to older patients. *Biology of Blood and Marrow Transplantation*, 22(9): 1543-51, 2016.
19. Narra R, Pingali SR, **Fenske TS**. "Early stage Hodgkin lymphoma," in Hospital Physician Hematology Board Review Manual. (2017), Jacobsen ED (editor). In press.
20. Narra R, Randhawa J, **Fenske TS** "Advanced-stage and relapsed/refractory Hodgkin lymphoma," in Hospital Physician Hematology Board Review Manual. (2017), Jacobsen ED (editor). In preparation.
21. Sriram D, Lakhotia R, **Fenske TS**. Circulating tumor DNA as a monitoring strategy in lymphoma. *Clinical Advances in Hematology & Oncology* 17(9): 509-17, 2019.
22. **Fenske TS**. Commentary: Is there a role for allogeneic hematopoietic cell transplantation in primary mediastinal large B-cell lymphoma? *Biology of Blood and Marrow Transplantation* 25(12): e354-e355, 2019.
23. Dreger P, **Fenske TS**, Montoto S, Pasquini MC, Sureda A, Hamadani M. Cellular immunotherapy for refractory DLBCL in the CART era: still a role for allogeneic transplantation? *Biology of Blood and Marrow Transplantation* 26(4): e77-e85, 2020.
24. \*Hammons L, **Fenske TS**. Treatment of mantle cell lymphoma in the frontline setting: are we ready for a risk-adapted approach? *Journal of Personalized Medicine* 12(7): 134, 2022
25. **Fenske TS**. Frontline therapy in mantle cell lymphoma: when clinical trial and real world data collide. *Journal of Clinical Oncology* 41(3): 452-459, 2023.
26. \*George G, **Fenske TS**. "Aggressive B-cell Non-Hodgkin Lymphoma," in Hospital Physician Hematology Board Review Manual, Litchkofski R (editor), May/June 2018.

### **Abstracts**

1. **Fenske TS**, Majewski DM, Baxter-Lowe LA. Use of oligotyping to detect novel HLA-DQ alleles and to assess linkage disequilibrium between HLA-DQA1 and HLA-DQB1 alleles. *Human Immunology* 34 (suppl 1): 20, 1992. 1992 American Assn. of Immunology Annual Meeting (Minneapolis, MN).
2. **Fenske TS**, Farmer NL, de Jong JLO, O'Shea JJ, Sondel PM. Interleukin-2 mediated activation of JAK3 in the absence of a detectable 64 kDa common gamma chain. *FASEB Journal* 10 (6): A1303, 1996. 1996 FASEB/ASBMB Annual Meeting. (New Orleans, LA - selected for oral presentation, given by T. Fenske).
3. **Fenske TS**. Bilateral leg pain and weakness in a patient with polycythemia vera. American College of Physicians / American Society of Internal Medicine, Wisconsin Chapter, Annual Meeting, Sept 2001. (Milwaukee, WI - Poster and oral presentation, given by T. Fenske).
4. **Fenske TS**, Kahl BS, Smith EP, Atkinson E, Garry-McCoy A, Mitchell TL, Eckstein L, Flynn B, McMannes J, Eickhoff J, Longo WL. High dose therapy with thioetpa, etoposide, total body irradiation and involved field radiation followed by autologous stem cell rescue for indolent histology and mantle cell non-Hodgkin lymphoma. 2002 ASH Annual Meeting, Abstract 5461 (Philadelphia, PA).
5. **Fenske TS**, Mathews V, Pengue G, Hanson P, Bogue M, McLeod HL, Graubert TA. Genetic basis of susceptibility to alkylator chemotherapy-related leukemia. 2003 ASH Annual Meeting, Abstract 1348. (San Diego, CA - selected for poster session, presented by T. Fenske).
6. Pengue G, Mathews V, **Fenske T**, Hanson P, Marrus S, Riaz N, Graubert TA. Targeting AML1-ETO to the hematopoietic stem cell compartment induces myeloproliferative disease in mice. 2003 ASH Annual Meeting, Abstract 756. (San Diego, CA - selected for oral presentation, given by T. Fenske).
7. Devine SM, Hallemeier C, **Fenske T**, Vij R, DiPersio JF, Adkins DA. Reduced intensity allografts for acute myeloid leukemia: defining the role of conditioning and donor alloreactivity. 2004 ASH Annual Meeting (San Diego, CA).
8. Edwin D, McMahon C, Kreisel F, Bogue M, **Fenske TS**, Graubert TA. A mouse model of alkylator-induced myelodysplastic syndrome. 2005 American Society of Hematology Annual Meeting (Atlanta, GA - oral presentation).

9. Edwin D, **Fenske TS**, McMahon C, Mathews V, Bogue M, Province M, Cheverud J, McLeod H, Graubert TA. Susceptibility to alkylator-induced cancer is a heritable trait. 2005 American Society of Hematology Annual Meeting (Atlanta, GA - poster).
10. Field JJ, **Fenske TS**, Blinder MA. Rituximab for the treatment of high titer acquired factor VIII inhibitors refractory to conventional chemotherapy. 2005 American Society of Hematology Annual Meeting (Atlanta, GA - poster).
11. Benjamin H, **Fenske TS**, Kroft SH, Hohenwarter EJ, Rilling WS. Treatment of diffuse large B-cell lymphoma of the the liver with yttrium-90 microsphere embolization. 2007 American Society of Hematology Annual Meeting (Atlanta, GA).
12. **Fenske TS**, Hari P, Carreras J, Zhang M, Kamble R, Rizzo JD, van Besien K, Lazarus HM, Vose JM. Pre-transplant rituximab therapy is associated with improved progression-free and overall survival in patients undergoing autologous stem cell transplantation for diffuse large B-cell lymphoma (DLBCL). 2007 American Society of Hematology Annual Meeting (Atlanta, GA - selected for oral presentation, given by T. Fenske).
13. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Cashen AF, Blum KA, **Fenske TS**, Hurd DD, Goy A, DiPersio JF, Bartlett NL. A Phase II Multicenter Study of Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma. 2009 American Society of Hematology Annual Meeting (New Orleans, LA).
14. Randhawa J, Bredeson C, **Fenske T**, Hari P, Palmer J, Saad A, Olteanu H, Atallah E. Outpatient Hypomethylating therapy for acute myelogenous leukemia (AML) can induce sustained responses with low induction mortality. 2009 American Society of Hematology Annual Meeting (New Orleans, LA).
15. Connelly J, Harrington A, Kroft S, Ho K, **Fenske T**, Malkin M. Methotrexate-induced CNS Hodgkin-like lymphoproliferative disorder: a case report. 2009 Joint Meeting of the Society for NeuroOncology and the American Association of Neurological Surgeons / Congress of Neurological Surgeons (New Orleans, LA).
16. Hari P, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, **Fenske TS**. Allogeneic transplantation (AlloHCT) for patients with mantle cell lymphoma (MCL) progressing after autologous transplantation (AutoHCT). 2011 International Conference on Malignant Lymphoma (Lugano, Switzerland).
17. **Fenske TS**, Carreras J, Zhang M, Laport G, Montoto S, Maloney D, Hari P. Outcomes of patients with mantle cell lymphoma undergoing autologous versus reduced-intensity allogeneic transplantation. 2011 International Conference on Malignant Lymphoma (Lugano, Switzerland).
18. Vose JM, Carter SL, Burns L, Ayala E, Press O, Moskowitz C, Stadtmauer E, Mineshi S, Ambinder R, **Fenske T**, Difronzo N, Horowitz M, Tomblyn M. Randomized phase III trial of 131 Iodine-tositumomab (Bexxar)/carmustine, etoposide, cytarabine, melphalan (BEAM) vs. rituximab/BEAM and autologous stem cell transplantation for relapsed diffuse large B-cell lymphoma (DLBCL): no difference in progression-free (PFS) or overall survival (OS). 2011 American Society of Hematology Annual Meeting (San Diego, CA).
19. Cornell RF, Thompson J, Drobyski WR, **Fenske TS**, Horowitz MM, Palmer JM, Pasquini MC, Saad AA, Rizzo JD, Saber W, Zhang MJ, Zhong X, Hari P. Risk factors and clinical features of autologous graft-versus-host disease/ engraftment syndrome after autologous hematopoietic cell (HCT) transplantation. 2012 Tandem BMT Meetings (San Diego CA).
20. Fehniger TA, Larson S, Trinkaus K, Siegel MJ, Hurd DD, Blum KA, Goy A, **Fenske TS**, Cashen AF, Wagner-Johnston N, Carson K, Bartlett NL. A phase II multicenter study of continuous dose lenalidomide in relapsed or refractory classical Hodgkin lymphoma. 2012 American Society of Hematology Annual Meeting (Atlanta, GA).
21. Chang JE, Zhang C, Kim K, Kirby R, Volk L, Wernkli J, Go R, Weiss M, Blank J, Farnen J, Cole C, Bseiso A, Volk M, Bayer G, Traynor A, Mansky P, **Fenske TS**, Kahl BS. Bendamustine + rituximab (BR) chemoimmunotherapy and maintenance lenalidomide in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): A Wisconsin Oncology Network (WON) Study. 2012 American Society of Hematology Annual Meeting (Atlanta, GA).
22. Wirk B, Burns L, **Fenske TS**, Hu Z, Laport G, Montoto S, Maloney D, Saber W. Clinical outcomes of hematopoietic cell transplantation in patients with diffuse large B cell lymphoma transformed from follicular lymphoma. 2013 Tandem BMT Meetings, Oral Presentation (Salt Lake City, UT).
23. \*Xia C, Zhong X, Dhokal B, Thompson J, **Fenske T**, Esselmann J, Keever-Taylor C, Padmanabhan A, Hari P. Plerixafor overcomes the adverse effect of diabetes on hematopoietic progenitor cell mobilization. 2013 Tandem BMT Meetings (Salt Lake City, UT).
24. Hintzke M, **Fenske T**, Kroft SH, Olteanu O, Harrington AM. CD30 expression in non-Hodgkin B-cell

- lymphoma. 2013 United States & Canadian Academy of Pathology Annual Meeting (Baltimore, MD).
25. \*Cornell RF, \*Randhawa JK, Drobyski W, Zhong X, \*Thompson J, Horowitz MM, **Fenske T**, Palmer J, Pasquini MC, Saber W, Thomas M, Zhang M, Hari PN. Risk factors and clinical features of engraftment syndrome after autologous hematopoietic cell transplantation (AHCT). 2013 Tandem BMT Meetings, Oral Presentation, (Salt Lake City, UT).
  26. \*Giever TA, Richter EL, Broge KM, Foy PC, Blust LS, Palmer JM, **Fenske TS**, Rilling WS, Hari P, Atallah EL. High incidence of venous thromboembolism in patients with hematological malignancies related to upper extremity peripherally inserted central venous catheters. 2013 American Society of Clinical Oncology Meeting, Poster (Chicago, IL).
  27. \*Pingali R, Jewell S, Bast M, Thompson J, Eastwood D, Bartlett NL, Armitage JO, Wagner-Johnston N, Vose JM, **Fenske TS**. Clinical or survival benefit to routine surveillance imaging in classical Hodgkin lymphoma patients in first complete remission. 2013 American Society of Clinical Oncology Meeting, Oral Presentation (Chicago, IL).
  28. Evens AM, Hamlin PA, Advani RH, Fanale M, Smith SM, Bociek G, **Fenske TS**, Petrich A, Winter J, Gordon L. Sequential brentuximab vedotin (BV) with adriamycin, vinblastine, and dacarbazine (AVD) for older patients with untreated Hodgkin Lymphoma: preliminary toxicity findings from a phase II window study. 2013 International Symposium on Hodgkin Lymphoma (Cologne, Germany).
  29. Gandhi MD, Petrich AM, Cassady R, Press O, Shah KA, Whyman JD, Lansigan F, Zelenetz A, \*Shah N, **Fenske T**, Hernandez-Ilizaliturri FJ, Lee JX, Barta SK, Karmali R, Camille A, Smith S, Vose J, Dalal N, Nabhan C, Peace D, Jovanovic B, Sohani A, Evens A, Castillo J, Abramson JS. Impact of induction regimen and consolidative stem cell transplantation in patients with double hit lymphoma (DHL): A large multicenter retrospective analysis. 2013 American Society of Hematology Meeting, Oral Presentation (New Orleans, GA).
  30. **Fenske TS**, Kim K, Zhang C, Farnen JP, Onitilo AA, Blank JH, Ahuja H, Wassenaar T, Qamar R, Mansky P, Traynor A, Mattison RJ, Kahl BS. Weekly temsirolimus and bortezomib for relapsed or refractory B-cell non-Hodgkin lymphoma: A Wisconsin Oncology Network Phase II study. 2013 American Society of Hematology Meeting, Poster (New Orleans, GA).
  31. Gandhi M, Evens A, **Fenske TS**, Hamlin P, Coiffier B, Ghosh N, Moskowitz A, Petrich A, Engert A, Lomasney J, Chadburn A, Wood GS, Salva K, Nardone B, Trifilio S, Raisch DW, West DP, Gordon LI, Winter JN. Pancreatitis in patients treated with brentuximab vedotin: A previously unrecognized serious adverse event. 2013 American Society of Hematology Meeting (New Orleans, GA).
  32. \*Pingali R, Vose JM, Wagner-Johnson N, Loberiza FR, **Fenske TS**, Jewell S, Bast M, Bartlett NL, Armitage JO. Lack of clinical benefit for routine surveillance imaging for diffuse large B-cell lymphoma in first complete remission. 2013 American Society of Hematology Meeting, Poster (New Orleans, GA).
  33. \*Graff T, \*Singavi A, Schmidt W, Eastwood D, Drobyski W, Horowitz M, Palmer J, Pasquini M, Rizzo D, Saber W, Hari P, **Fenske TS**. Safety of outpatient autologous hematopoietic cell transplantation (AuHCT) for multiple myeloma and lymphoma. 2014 Tandem BMT Meetings (Dallas, TX).
  34. \*Peswani N, Carlson KS, Chitambar CR, **Fenske TS**, Hari P, Michaelis L, Blust LS, Atallah H. Short time to ATRA administration and reduction of early mortality in patients with APL. 2014 American Society of Clinical Oncology Meeting (Chicago, IL).
  35. \*Chandran R, Gardiner SK, **Fenske TS**, Spurgeon SE. Survival trends in T cell prolymphocytic leukemia: a SEER database analysis. 2014 Ultmann Chicago Lymphoma Symposium (Chicago, IL).
  36. \*Peswani N, **Fenske T**, Hari P, Carlson KS, Michaelis L, Chitambar C, Baumann-Kreuziger L, Atallah E. D-dimer kinetics, chemotherapy and the risk of bleeding in patients with acute promyelocytic leukemia. 2014 World Congress on Controversies in Thrombosis and Hemostasis (Berlin, Germany).
  37. Burris HA, Patel MR, Brander D, O'Connor OA, Deng C, **Fenske TS**, Gutierrez M, Jones SF, Kuhn JG, Miskin HP, Sportelli P, Vakkalank S, Flinn I. TGR-1202 a novel once daily PI3K? inhibitor, demonstrates clinical activity with a favorable safety profile, lacking hepatotoxicity, in patients with chronic lymphocytic leukemia and indolent non-Hodgkin's lymphoma. 2014 American Society of Hematology Meeting (San Francisco, CA).
  38. Laport GG, Wu J, Logan B, Bachanova V, Hosing C, **Fenske T**, Longo W, Devine SM, Nadamane A, Gersten I, Horowitz M, Lazarus HM, Riches ML. Reduced intensity conditioning (RIC) with rituximab yields excellent outcomes after allogeneic hematopoietic cell transplantation (alloHCT) for relapsed follicular lymphoma (FL): A phase II multicenter trial from the Blood and Marrow Transplant Network (BMT CTN). 2014 American Society of Hematology Meeting (San Francisco, CA).
  39. Kritharis A, Kanakry JA, Sehn LH, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF,

- Advani RH, Klein AK, Nabhan C, Smith SM, Lossos IS, Press OW, **Fenske T**, Friedberg JW, Vose JM, Blum KA, Evens AM. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL): analysis of tumor immunophenotype and critical examination of therapy with associated impact on outcome. 2014 American Society of Hematology Meeting (San Francisco, CA).
40. \*Peswani N, Baumann-Kreuziger L, Carlson K, Michaelis L, Hari P, **Fenske T**, Chitambar C, Atallah E. D-dimer kinetics, chemotherapy, and the risk of bleeding in acute promyelocytic leukemia. 2014 American Society of Hematology Meeting (San Francisco, CA).
41. \*Nelson A, Eastwood D, Wang T, Carlson K, Michaelis L, Pasquini M, Hari P, Chitambar C, **Fenske T**, Graham M, Hamadani M, D'Souza A, Atallah E. A statistical model for predicting neutropenic fever. 2014 American Society of Hematology Meeting (San Francisco, CA).
42. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, \*Shah N, **Fenske TS**, Jaso J, Medeiros LJ, Yang DT, Nabhan C. Comparative analysis of "double-hit" lymphoma cases by genetic subtype. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
43. Veltri L, Dhakal B, Singavi A, Wen S, Luo J, Craig M, Cumpston A, Shillingburg A, Watkins K, Esselman J, Pasquini MC, **Fenske TS**, Hari P, Hamadani M, Kanate AS. Chemomobilization with ICE (ifosfamide, carboplatin and etoposide) is superior to G-CSF and plerixafor (G+P) mobilization in lymphoid malignancies. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
44. Diefenbach CS, Li H, Kahl BS, Robertson MJ, Cohen J, Advani RH, Ambinder R, **Fenske TS**, Ansell SM. A phase 1 study with an expansion cohort of the combination of ipilimumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
45. \*Giever TA, Giever ER, Foy PC, Baumann-Kreuziger L, Michaelis L, Carlson K, **Fenske TS**, Hamadani M, Rilling WE, Hari PN, Atallah EL. Incidence of line related venous thromboembolism in peripherally inserted central venous catheters via the brachiocephalic veins vs tunneled chest central venous catheters via the internal jugular vein in patients with hematologic malignancies. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
46. \*Nelson A, Eastwood D, Wang T, Carlson K, Michaelis LC, Pasquini MC, Hari P, Chitambar CR, **Fenske TS**, Graham MB, Hamadani M, D'Souza A, Atallah E. A statistical model for predicting neutropenic fever. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
47. Burris HA, Patel MR, **Fenske TS**, O'Connor OA, Deng C, Brander DM, Gutierrez M, Jones S, Kuhn J, Miskin HP, Sportelli P, Vakkalanka S, Flinn I. TGR-1202, a Novel Once Daily PI3K $\gamma$  Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile, Lacking Hepatotoxicity, in Patients with Chronic Lymphocytic Leukemia and B-Cell Lymphoma. 2015 American Society of Clinical Oncology Meeting (Chicago, IL).
48. Chen R, Li H, Bernstein SH, Rimsza LM, Forman SJ, Constine LS, Shea TC, Cashen AF, **Fenske TS**, Barr PM, Leblanc M, Fisher RI, Smith SM, Friedberg JW. Results of a randomized phase II trial of R-HCVAD vs R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma: US Intergroup Study SWOG S1106. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
49. Landsburg DJ, Petrich AM, Abramson JS, Sohani AR, Press O, Cassaday R, Chavez JC, Song K, Zelenetz AD, Gandhi M, Shah N, **Fenske TS**, Jaso J, Medeiros LJ, Yang DT, Nabhan C. Analysis of "double-hit" lymphoma cases by genetic subtype. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
50. Evens AM, Kanakry JA, Sehn LH, Kritharis A, Feldman T, Kroll A, Gascoyne RD, Petrich AM, Abramson JS, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Adeimy C, Hemminger J, Bartlett NL, Mato A, Caimi PF, Advani RH, Klein AK, Nabhan C, Smith SM, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA. Gray zone lymphoma (GZL) with features intermediate between classical Hodgkin lymphoma (HL) and diffuse large B-cell lymphoma (DLBCL): characteristics, outcomes, and prognostication among a large multicenter cohort. 2015 International Conference on Malignant Lymphoma (Lugano, Switzerland).
51. O'Brien S, Burris H, Patel M, Buger M, **Fenske T**, O'Connor O, Brander D, Schreeder M, Miskin H, Sportelli P, Flinn I. TGR-1202, a novel once daily PI3K $\delta$  inhibitor, demonstrates clinical activity with a favorable & differentiated safety profile as a single agent and in combination with a novel glycoengineered anti-CD20 mAb, ublituximab, in patients with rel/ref CLL. 2015 International Workshop on Chronic Lymphocytic Leukemia (Sydney, Australia).



52. **Fenske TS**, \*Graff TM, Ahn KW, DiGilio A, Smith SM, Sureda AM, Hamadan M. Reduced-intensity allogeneic hematopoietic cell transplantation (allo-HCT) provides durable progression-free survival (PFS) in a subset of diffuse large B-cell lymphoma (DLBCL) patients relapsing after autologous (auto) HCT. 2015 American Society of Hematology Meeting (Orlando, FL).
53. Chen R, Li H, Bernstein SH, Rimsza LM, Forman SJ, Constine LS, Shea TC, Cashen AF, Blum K, **Fenske TS**, Barr PM, Leblanc M, Fisher RI, Smith SM, Faham M, Wilkins J, Leonard JP, Kahl BS, Friedberg JW. Pre-transplant R-Bendamustine induces high rates of minimal residual disease in MCL patients: Updated results of SWOG S1106: US intergroup study of a randomized phase II trial of R-HCVAD vs. R-bendamustine followed by autologous stem cell transplants for patients with mantle cell lymphoma . 2015 American Society of Hematology Meeting (Orlando, FL).
54. Mussetti A, Kanate AS, Kharfan-Dabaja MA, Ahn KW, DiGilio A, Ciurea S, Armand P, Salit R, **Fenske TS**, Smith SM, Sureda A, Bolanos Meade J, Hamadani M. Survival after T-cell replete haploidentical related donor transplant using post-transplant cyclophosphamide compared with matched unrelated donor (MUD) transplant for lymphoma malignancies. 2015 American Society of Hematology Meeting (Orlando, FL).
55. \*Kapke JT, \*Epperla N, \*Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with classical Hodgkin's lymphoma (cHL) undergoing autologous hematopoietic cell transplantation (auto-HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
56. \*Epperla N, \*Shah N, Richardson K, Carrum G, Hari P, Hamadani M, Pingali SR, Karmali R, **Fenske TS**. Impact of routine surveillance imaging on outcomes in patients with diffuse large B-cell lymphoma (DLBCL) undergoing autologous hematopoietic cell transplantation (auto-HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
57. Diefenbach CS, Hong F, Cohen JB, Robertson MJ, Ambinder RF, **Fenske TS**, Advani RH, Kahl BS, Ansell SM. Preliminary Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2015 American Society of Hematology Meeting (Orlando, FL).
58. \*Dhakal B, \*Epperla N, Ramalingam S, Shuff J, Rein L, Banerjee A, Siker M, Hoskin P, Hari P, D'Souza A, Atallah E, **Fenske TS**, Erickson B, Hamadani M. Local control of ocular adenexal lymphoproliferative disorders (OALD): similar outcomes in MALT and non-MALT histologies. 2015 American Society of Hematology Meeting (Orlando, FL).
59. O'Connor OA, Flinn I, Patel MR, **Fenske TS**, Deng C, Brander DM, Gutierrez M, Jones S, Kuhn J, Miskin HP, Sportelli P, Vakkalanka S, Burris HA. TGR-1202, a Novel Once Daily PI3K? Inhibitor, Demonstrates Clinical Activity with a Favorable Safety Profile in Patients with CLL and B-Cell Lymphoma. 2015 American Society of Hematology Meeting (Orlando, FL).
60. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske T**, Finel H, Schouten H, Montoto S, Robinson S, Smith S, Boumendil A, Hamadani M, Pasquini M. Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). A Joint Study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). 2015 American Society of Hematology Meeting (Orlando, FL).
61. \*Singavi AK, \*Kapke JT, Levin A, Banerjee A, Visotcky A, Zhu F, Hamadani M, Hari PN, **Fenske TS**. Day 100 Absolute Lymphocyte Count (ALC) Predicts Risk of Serious Infections in Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT). 2015 American Society of Hematology Meeting (Orlando, FL).
62. Hamdani M, Pasquini MC, Visotcky A, Ahn KW, Boyd J, Rizzo JD, Saber W, Drobyski W, Arce-Lara C, D'Souza A, **Fenske TS**, Cumpston A, Bunner P, Craig M, Hari PN, Kanate AS. Prospective, Multicenter Phase II Clinical Trial of Atorvastatin-based Acute Graft-Versus-Host Disease (aGVHD) Prophylaxis in Recipients of HLA-Matched Related Donor (MRD) and Matched Unrelated Donor (MUD) Allogeneic Hematopoietic Cell Transplantation (alloHCT). 2016 Tandem BMT Meetings (Honolulu, HI).
63. Karmali R, Ghosh N, Rocha V, Ahn K, DiGilio A, Armande P, Salit R, **Fenske T**, Smith S, Sureda A, Wagner-Johnston N, Bolanos Meade J, Hamadani M. Survival after T-cell replete haploidentical related donor hematopoietic cell transplantation (Haplo-HCT) using post-transplant cyclophosphamide (PT-CY) compared with HLA-matched related donor (MRD) transplant for lymphoma. 2016 Tandem BMT Meetings (Honolulu, HI).
64. \*Thompson JR, Drobyski WR, D'Souza AD, **Fenske TS**, Hamadan M, Hari PN, Pasquini MC, Saber W, Rizzo JD. Etanercept for late onset idiopathic pneumonia syndrome. 2016 Tandem BMT Meetings

- (Honolulu, HI).
65. Sureda A, Zhang MJ, Dreger P, Carreras J, **Fenske TS**, Finel H, Schouten H, Montoto S, Robinson S, Smith SM, Boumendil A, Hamadani M, Pasquini M. Allogeneic transplantation for relapsed / refractory follicular lymphoma. A joint study between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR). 2016 European Blood and Marrow Transplantation Annual Meeting (Velencia, Spain).
  66. Voshtina E, Hamadani M, **Fenske T**, Pasquini T, D'Souza A, Saber W, Rizzo R, Drobyski W, Hari P, Shah N. Outcomes of obese elderly patients undergoing allogeneic transplant for myeloid malignancies. 2016 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
  67. \*Epperla N, Hamadani M, Ahn KW, Kanate AS, Calzada O, Farmer L, Tallarico M, Nabhan C, Costa LJ, Kenkre V, Ghosh N, Cohen J, Hari PH, Oak E, Cashen A, **Fenske TS**. Predictive factors and outcomes for ibrutinib therapy in relapsed/refractory (R/R) mantle cell lymphoma. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
  68. Burris HA, Flinn IW, Lunning M, Vose J, Fowler N, Nastoupil L, O'Brien S, Schreeder MT, Patel MR, **Fenske TS**, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin HP, Weiss MS, O'Connor OA. Long-term follow-up of the once-daily PI3K $\gamma$  inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Meta-analysis of TGR-1202 as a single agent and in combination with ublituximab. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
  69. \*Epperla N, Greenwell B, Staton AD, Lee MJ, Switchenko JM, Maly JJ, Blum KA, Grover NS, Mathews S, Park SI, Gordon MJ, Danilove AV, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Association of complex karyotype with inferior progression-free and overall survival in mantle cell lymphoma. 2016 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
  70. Burris HA, Flinn IW, Lunning M, Vose J, Fowler N, Nastoupil L, O'Brien S, Schreeder MT, Patel MR, **Fenske TS**, Brander DM, Siddiqi T, Flowers C, Burger JA, Wierda WG, Kuhn JG, Sportelli P, Miskin HP, Weiss MS, O'Connor OA. Long-term follow-up of the once-daily PI3K $\gamma$  inhibitor TGR-1202 demonstrates a differentiated safety profile and high response rates in CLL and NHL: Meta-analysis of TGR-1202 as a single agent and in combination with ublituximab. 2016 European Hematology Association Annual Meeting (Copenhagen, Denmark).
  71. Diefenbach CS, Hong F, Cohen JB, Robertson MJ, Ambinder RF, **Fenske TS**, Advani RH, Kahl BS, Ansell SM. (check title) Safety and Efficacy of the Combination of Brentuximab Vedotin and Ipilimumab in Relapsed / Refractory Hodgkin Lymphoma: A trial of the ECOG-ACRIN Cancer Research Group (E4412). 2016 International Symposium on Hodgkin Lymphoma (Cologne, Germany).
  72. Levin A, Kleman A, Rein L, Tarima S, Michaelis L, Carlson KS, Hamadani M, **Fenske TS**, Hari P, Atallah E, Dhakal B. Early mortality in patients with acute promyelocytic leukemia (APL) treated in community vs. academic hospitals. 2016 American Society of Hematology Meeting (San Diego, CA).
  73. Hamlin PA, Miller C, **Fenske TS**, Pandey A, Coffey GP, Birrell M, Leeds JM, Sabalvaro-Torres A, Kim Y, Curnutte JT, Michelson GC. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase IIa study in patients relapsed/refractory B cell malignancies. 2016 American Society of Hematology Meeting (San Diego, CA).
  74. Atallah E, Michaelis LC, Carlson KB, D'Souza A, **Fenske TS**, Pasquini MC, Hamadani M, Baim A, Guhl J, Hari P. Phase I study of combination chemotherapy plus ixazomib in adults with relapsed or refractory acute lymphoblastic leukemia/lymphoma (ALL). 2016 American Society of Hematology Meeting (San Diego, CA).
  75. \*Epperla N, Maddocks KJ, Chavez JC, Reddy N, Karmali R, Umyarova E, Costa C, Bachanova V, Glenn M, Calzada O, Xavier A, Zhou Z, Hossain NM, Hernandez-Ilizaliturri FJ, Al-Mansour Z, Barta SK, Chhabra S, Lansigan F, Mehta A, Jaglal MV, Evans A, Peker D, Forero-Torres A, Flowers C, **Fenske TS**, Cohen JB, Hamadani M, Costa LJ. Diffuse large B-cell lymphoma with primary treatment failure: Identification of ultra-high risk patients and benchmarking for experimental therapies. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
  76. \*Epperla N, Costa LJ, Reddy N, Maddocks KJ, Karmali R, Bachanova V, Umyarova E, Zhou Z, Glenn M, Chavez JC, Hernandez-Ilizaliturri FJ, Costa C, Hossain NM, Calzada O, Al-Mansour Z, Xavier A, Evens A, Chhabra S, Jaglal MV, Barta SK, Lansigan F, Flowers C, **Fenske TS**, Cohen JB, Hamadani M. Primary failure diffuse large B-cell lymphoma: early autologous or donor hematopoietic cell transplantation no effective in patients with ultra-high risk features. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
  77. Pilichowska M, Pittaluga S, Ferry JA, Hemminger J, Kanakry JA, Sehn LH, Feldman T, Abramson JS,

- Hernandez-Iizaliturri FJ, Lossos IS, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Gupta G, Gascoyne RD, Evens AM, Jaffe E. Gray zone lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): pathologic classification and clinical outcomes from a multicenter consensus analysis. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
78. Landsburg DJ, Reddy NM, Howlett C, Mato AR, Kaplan JB, Behdad A, Petrich AM, Maly J, Blum KA, Chavez JC, Shaoying L, Medeiros LJ, Falkiewicz MK, Hill BT, \*Singavi A, **Fenske TS**, Gerson J, Barta SK, Pallawi T, Hernandez-Iizaliturri, Costa C, Lansigan F, Calzada O, Cohen J, Lue JK, Amengual JE, Rivera X, Persky DO, Peace DJ, Cassaday RD. Benefit of consolidative autologous stem cell transplantation in first complete remission for patients with double hit lymphoma appears dependent on induction regimen intensity. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
79. Voshtina E, Dzabo A, Hamadani M, **Fenske TS**, D'Souza A, Saber W, Drobyski W, Hari P, Shah N. Outcomes of obese elderly patients undergoing allogeneic stem cell transplant for myeloid malignancies. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
80. \*Epperla N, Staton AD, Greenwell B, Switchenko JM, Maly JJ, Blum KA, Grover N, Mathews S, Park SI, Gordon M, Danilov A, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Risk stratification of mantle cell lymphoma patients using MIPI, Ki67 percentage and complex cytogenetics. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
81. Haverkos BM, Schowinsky J, Kaplan JB, Kamdar M, Kanate AS, Saad A, Ganguly S, Flowers M, **Fenske TS**, Hari P, Hamadani M, Lowsky R, Andritsos L, Jagasia M, Brown S, Armand P, Merryman R, Bachanova V, Stephens D, Nakamura R, Gutman J, Devine SM. Checkpoint blockade for treatment of lymphoma following allogeneic stem cell transplant: use may be complicated by onset of severe acute graft versus host disease. 2016 American Society of Hematology Annual Meeting (San Diego, CA).
82. Kanate AS, Olteanu H, Ahn KW, DiGilio A, Sureda A, **Fenske TS**, Smith SM, Hamadani M. Allogeneic hematopoietic cell transplantation (alloHCT) for extranodal natural killer (NK)/T-Cell Lymphoma, Nasal Type (ENKL): A CIBMTR analysis. 2017 Tandem BMT Meetings (Orlando, FL).
83. \*Epperla N, Ahn KW, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine SM, Jaglowski S, Kharfan-Dabaja M, Rezvani A, Smith SM, Sureda S, **Fenske TS**, Hamadani M. Rituximab (R) versus non-rituximab (NR) containing reduced intensity conditioning (RIC) regimens for allogeneic hematopoietic cell transplantation (alloHCT) in B-cell non-Hodgkin lymphomas (B-NHL): A CIBMTR analysis. 2017 Tandem BMT Meetings (Orlando, FL).
84. Casulo C, Friedberg JW, Ahn KW, DiGilio A, Sureda A, **Fenske TS**, Smith SM, Hamadani M. Autologous transplantation (autoHCT) is associated with improved overall survival (OS) in follicular lymphoma (FL) patients (pts) experiencing early therapy failure after frontline chemo-immunotherapy: A National Lymphocare Study (NLCS) & CIBMTR Analysis. 2017 Tandem BMT Meetings (Orlando, FL).
85. Drobyski W, Szabo A, Hari P, Hamadani M, Herbert K, Keever-Taylor C, D'Souza A, Eapen M, **Fenske TS**, Horowitz MM, Rizzo JD, Saber W, Shah N, Shaw BE, Yim S, Pasquini MC. Results of a phase II clinical trial of tocilizumab, tacrolimus and methotrexate (Toc/Tac/MTX) for the prevention of acute graft versus host disease (GVHD) and matched case control comparison to Tac/MTX after allogeneic stem cell transplantation. 2017 Tandem BMT Meetings (Orlando, FL).
86. \*Epperla N, Shah NN, He F, Kodali D, Kleman A, Ahn KW, Hari PN, Pasquini M, D'Souza AD, Saber W, **Fenske TS**, Craig MD, Kanate AS, Bachanova V, Hamadani M. Post-relapse survival in lymphoma patients after experiencing therapy failure following allogeneic hematopoietic cell transplantation. 2017 Tandem BMT Meetings (Orlando, FL).
87. Greenwell IB, Valla K, Caulfield S, Switchenko JM, Staton A, Flowers C, Maly J, Blum KA, Park SI, Danilov AV, Epperla N, **Fenske TS**, Hamadani M, Cohen JB. Outcomes in mantle cell lymphoma for elderly patients undergoing autologous stem cell transplant in CR1. 2017 Tandem BMT Meetings (Orlando, FL).
88. Abidi MA, Stoll C, D'Souza A, Pasquini MC, Saber W, **Fenske TS**, Rizzo JD, Drobyski W, Keever-Taylor CA, Hari, P. Importance of site preparation in reducing the risk of bacterial contamination during bone marrow harvest. 2017 Tandem BMT Meetings (Orlando, FL).
89. \*Epperla N, **Fenske TS**, Costa L. MYC+ Relapsed and Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Impact of additional "hits" and outcomes with subsequent therapy. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
90. Godfrey J, Smith SM, Ahn KW, Digilio A, **Fenske T**, Sureda A, Hamadani M. Autologous (auto) Versus Matched Sibling Donor (MSD) or Matched Unrelated Donor (MUD) Allogeneic (allo) Hematopoietic

Cell Transplantation (HCT) in Follicular Lymphoma (FL) Patients (pts) with Early Chemoimmunotherapy Failure (ECF): A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).

91. \*Epperla N, Strelec LE, Saba R, Kodali D, Esan O, Yang DT, Mato AR, Hamadani M, **Fenske TS**, Kenkre VP, Kanate AS, Svoboda J, Cashen AF, Shah NN. Assessment of optimal management of grade 3A follicular lymphoma (FL3A): a multicenter study. 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
92. Andreadis C, **Fenske TS**, Hill BT, Stiff PJ, Grenblatt DL, His ED, Kelley T, Richards KL, Kostakoglu L, Schoder H, Jung SH, Pitcher B, Pike K, Plona T, Baugher R, Mellott S, Bartlett NL, Leonard J, Shea TC, Devine SM. IRONCLAD: A randomized phase III study of ibrutinib Or No Consolidation following autologous hematopoietic stem cell transplantation (AutoHCT) for relapsed/refractory Activated B-cell (ABC) subtype diffuse large B-cell lymphoma (DLBCL). 2017 American Society of Clinical Oncology Annual Meeting, (Chicago, IL).
93. Hamlin JA, Farber C, **Fenske TS**, Khatcheressian J, Miller C, Munoz J, Patel M, Smith S, Stevens D, Pandey A, Birrell M, Leeds JM, Wang YL, Coffey GP, Curnutte JT. The dual SYK/JAK inhibitor cerdulatinib demonstrates complete inhibition of SYK and JAK and rapid tumor responses in a phase 2 study in patients with relapsed/ refractory B cell malignancies. 2017 European Haematology Association (Madrid, Spain).
94. Hamlin JA, Farber C, **Fenske TS**, Khatcheressian J, Miller C, Munoz J, Patel M, Schreeder M, Smith S, Stevens D, Pandey A, Birrell M, Leeds JM, Wang YL, Coffey GP, Curnutte JT. The dual SYK/JAK inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/ refractory B cell malignancies. 2017 International Conference on Malignant Lymphoma (Lugano, Switzerland).
95. \*Badhar T, Hamadani, M, Bachanova V, Maddocks KJ, Umyarova E, Chavez JC, Epperla N, Chhabra S, Xavier A, Karmali R, Salhab M, Reddy N, Hernandez-Ilizaliturri FJ, Flowers, C, Evens AW, Zhou Z, Lansigan F, Barta SK, Cohen JB, **Fenske TS**, Costa LJ. Efficacy of salvage chemotherapy in diffuse large B-cell lymphoma with primary treatment failure according to putative cell of origin. 2017 American Society of Hematology Annual Meeting (Atlanta, GA).
96. Gerson JN, Barta SK, Villa D, Gerrie AS, Li S, Medeiros J, Wang M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, **Fenske TS**, Narayana S, Maddocks KJ, Bond DA, Lansigan DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan J, Umyarova E, Pulluri B, Amengual JE, Lue JK, Caimi P, Cohen JB, Calzada O, Handorf E, Anderson JK, Chapni P, Bachanova V, Rajguru S, Churnetski MC, Diefenbach C, Bast M, Kovach AE. Consolidation with autologous hematopoietic cell transplant in first remission improves overall survival in younger patients with mantle cell lymphoma in the rituximab era. 2017 American Society of Hematology Annual Meeting (Atlanta, GA).
97. Chhabra S, Hari PN, Visotcky A, Shah NN, Pasquini MC, Rizzo JD, Saber W, D'Souza A, Dhakal B, Anshu A, Thompson R, **Fenske TS**, Shaw BE, Drobyski WR, Hamadani M. Ixazomib for chronic graft-versus-host disease (cGVHD) prophylaxis in patients undergoing allogeneic transplantation (alloHCT): preliminary results of a phase I/II study. 2017 American Society of Hematology Annual Meeting (Atlanta, GA).
98. Greenwell IB, Switchenko JM, Staton AD, Saxe DF, Maly J, Blum KA, Grover N, Matthew S, Park SI, Gordon MJ, Danilov A, \*Epperla N, **Fenske TS**, Hamadani M, Flowers CR, Cohen JB. Complex karyotype predicts the prognostic impact of WBC count in untreated mantle cell lymphoma and is associated with shortened survival independent of specific cytogenetic abnormalities. 2017 American Society of Hematology Annual Meeting (Atlanta, GA).
99. Evens AM, Pilichowska M, Pittaluga S, Ferry J, Hemminger J, Change H, Kanakry JA, Sehn LH, Feldman TA, Hernandez-Ilizaliturri FJ, Lossos IS, Abramson JS, Kritharis A, Press OW, **Fenske TS**, Friedberg JW, Vose JM, Blum KA, Jagadeesh D, Woda B, Gascoyne RD, Jaffe E. Gray zone lymphoma (GZL) with features intermediate between diffuse large B-cell lymphoma (DLBCL) and classical Hodgkin lymphoma (cHL): a pathologic consensus study with patient outcomes and prognostication across 15 North American centers. 2017 American Society of Hematology Annual Meeting (Atlanta, GA).
100. Caulfield S, Schlafer D, Switchenko JM, Greenwell IB, Staton AS, Blum KA, Grover N, Park SI, Danilov A, \*Epperla N, **Fenske TS**, Hamadani M, Gordon MJ, Mathews S, Valla K, Flowers C, Cohen JB. Initial salvage approaches for relapsed/refractory mantle cell lymphoma have comparable response rates, progression-free and overall survival. 2017 American Society of Hematology Annual Meeting (Atlanta, GA).

101. Badar T, Hari P, Chhabra S, Dhakal B, Drobyski W, **Fenske TS**, Hamadani M, Horowitz M, Pasquini M, Rizzo D, Saber W, Shah N, Shaw B, D'Souza A. Use of prophylene glycol-free melphalan conditioning in light chain amyloidosis patients undergoing autologous hematopoietic cell transplantation is associated with significantly lower hospitalization days. 2018 Tandem BMT Meetings (Salt Lake City, UT).
102. Shah NN, Ahn KW, Litovich C, Sureda A, Smith SM, **Fenske TS**, Hamadani M. Outcomes of patients 65 years and older with non-Hodgkin lymphoma receiving reduced-intensity conditioning allogeneic hematopoietic stem cell transplantation compared to patients 55-64 years of age: a CIBMTR analysis. 2018 Tandem BMT Meetings (Salt Lake City, UT).
103. Hamadani M, Ahn KW, Litovich C, Finel H, Smith SM, **Fenske TS**, Boumendil A, Sietrich S, Robinson S, Montoto S, Dreger P, Sureda A. Post-transplant cyclophosphamide (PT-Cy) based haploidentical transplantation (haploHCT) versus matched sibling (MSD) or mismatched unrelated donor (MUD) reduced intensity (RIC) HCT for diffuse large B-cell lymphoma (DLBCL): A CIBMTR & EBRT Analysis. 2018 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
104. Diefenbach C, Hong F, Ambinder R, Cohen J, Robertson M, David K, Advani R, **Fenske T**, Barta S, Palmisano N, Svoboda J, Morgan D, Kahl B, Ansell S. No significant increased immune toxicity in post-transplant patients treated with brentuximab vedotin in combination with immune checkpoint blockade. 2018 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
105. Hamlin PA, Cheson BD, Farber CM, Feldman T, **Fenske TS**, Hess BT, Khatcheressian JL, Miller CB, Munoz J, Patel MR, Smith SM, Stevens DA, Ye JC, Steele A, Pandey A, Birrell MR, Leeds JM, Coffey GP, Curnutte JT. The dual Syk/Jak inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2 study in patients with relapsed/refractor B and T cell malignancies. 2018 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
106. Dreger P, Sureda A, Ahn K, Finel H, Tischer J, Castagna L, Blaise D, Dominiotto A, Schmid C, Ciceri F, Boumendil A, Litovich C, Smith S, **Fenske T**, Dietrich S, Robinson S, Montoto S, Hamadani M. Reduced-intensity allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma: comparable outcomes of haplo-identical vs. fully matched related donors. A CIBMTR & EBMT analysis. 2018 European Hematology Association (Stockholm, Sweden).
107. Hamlin P, Cheson BD, Farber CM, Feldman T, **Fenske TS**, Hess BT, Khatcheressian JL, Miller CB, Munoz J, Patel MR, Smith SM, Smith SD, Stevens DA, Ye JC, Steele AJ, Pandey A, Birrell MR, Leeds JM, Coffey GP, Curnutte JT. The dual Syk/Jak inhibitor cerdulatinib demonstrates rapid tumor responses in a phase 2A study in patients with relapsed/refractory B- and T-cell non-Hodgkin lymphoma (NH). 2018 European Hematology Association (Stockholm, Sweden).
108. Diefenbach C, . . . **Fenske T** . . . A phase I study with an expansion cohort/ randomized phase II study of the combinations of ipilimumab, nivolumab and brentuximab vedotin in patients with relapsed/refractory Hodgkin lymphoma: a trial of the ECOG-ACRIN Research Group (E4412: Arms G-D). 2018 American Society of Hematology Annual Meeting (San Diego, CA).
109. Guru M, Szabo A, Hamadani M, **Fenske TS**, Shah NN. Outcomes of advanced stage classical Hodgkin lymphoma in the United States: analysis of the Surveillance Epidemiology and End Results database. 2018 American Society of Hematology Annual Meeting (San Diego, CA).
110. Badar T, Epperla N, Szabo A, Borson S, Vaughn J, George G, Shah N, Hamadani M, Cashen A, **Fenske TS**. Trends in survival of classical Hodgkin lymphoma patients after failed autologous hematopoietic cell transplantation. 2018 American Society of Hematology Annual Meeting (San Diego, CA).
111. Shanmugasundaram K, Goyal S, Switchenko J, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson J, Barta S, Maldonado E, Gordon M, Danilov A, Grover NS, Burkhart M, Karmali R, Sawalha Y, Hill B, Ghosh N, Park SI, Epperla N, Bond D, Badar T, Blum KA, Hamadani M, **Fenske TS**, Malecek M, Kahl BS, Flowers CR, Cohen JB. Intensive Induction Regimens in Mantle Cell Lymphoma Patients who Defer Therapy is Not Associated with Improved Progression-free or Overall Survival. 2018 American Society of Hematology Annual Meeting (San Diego, CA).
112. Shah NN, Zhu F, Taylor C, Schneider D, Kruger W, Worder A, **Fenske TS**, Hamadani M, Johnson B, Dropulic B, Orentas RJ, Hari P. Phase 1 study with point-of-care manufacturing of dual targeted, tandem anti-CD19, anti-CD20 chimeric antigen receptor modified T (CAR-T) cells for relapsed, refractory, non-Hodgkin lymphoma (NHL). 2018 American Society of Hematology Annual Meeting (San Diego, CA).
113. Kamdar M, Li H, Chen R, Rimsza LM, Leblanc M, **Fenske TS**, Barr PM, Phillips T, Leonard JP, Kahl BS, Friedberg JW, Smith SM. Five-year outcomes of SWOG S1106: A randomized phase II US Intergroup study of R-HCVAD vs. R-Bendamustine followed by autologous stem cell transplant for patients with

- mantle cell lymphoma. 2018 American Society of Hematology Annual Meeting (San Diego, CA).
114. Dhakal B, Giri S, Levin A, Rein L, **Fenske TS**, Chhabra S, Shah N, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani H. Incidence and predictors of 30-day readmissions following autologous hematopoietic cell transplantation (auto-HCT) in the U.S. 2018 American Society of Hematology Annual Meeting (San Diego, CA).
  115. Dhakal B, Giri S, Levin A, Rein R, **Fenske TS**, Chhabra S, Shah N, Szabo A, D'Souza A, Pasquini M, Hari P, Hamadani H. Association between transplant volumes and 30-day readmissions following allogeneic hematopoietic cell transplantation (allo-HCT) in the U.S. 2018 American Society of Hematology Annual Meeting (San Diego, CA).
  116. Epperla N, Badar T, Szabo A, Vaughn J, Borson S, Shah NN, Hamadani M, Cashen A, **Fenske TS**. Post-relapse survival in diffuse large B-cell lymphoma patients after experiencing therapy failure following autologous hematopoietic cell transplantation. 2019 Transplant & Cellular Therapy Meeting (Houston, TX).
  117. Chhabra S, Hari PN, Visotcky A, Zhu F, Shah NN, Rizzo JD, Saber W, D'Souza A, Dhakal B, Abedin S, Runaas L, Cantrall K, **Fenske TS**, Horowitz MM, Shaw BE, Drobyski WR, Pasquini MC, Hamadani M. A phase 1/2 study of ixazomib for chronic graft-versus-host disease (cGVHD) prophylaxis after allogeneic transplantation (alloHCT). 2019 Transplant & Cellular Therapy Meeting (Houston, TX).
  118. Hill BT, Switchenko JM, Martin P, Chumelski M, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Bond D, Badar T, Blum KA, Guo J, Hamadani M, **Fenske TS**, Malecek M, Kahl BS, Flosers CR, Cohen JB. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab (BR). 2019 International Conference on Malignant Lymphoma (Lugano, Switzerland).
  119. Bond DA, Switchenko JM, Maddocks K, Churnetski M, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova B, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, **Fenske TS**, Malacek M, Kahl BS, Flowers CR, Blum KA, Cohen JB. Outcomes for patients with mantle cell lymphoma experiencing frontline treatment failure: a multicenter retrospective study. 2019 International Conference on Malignant Lymphoma (Lugano, Switzerland).
  120. Diefenbach CS, Hong F, Ambinder R, Cohen J, Robertson M, David K, Advani R, **Fenske T**, Barta S, Palmisano N, Svoboda J, Morgan D, Karmali R, Kahl B, Ansell S. Extended follow up of a phase I trial of ipilimumab, nivolumab and brentuximab vedotin in relapsed Hodgkin lymphoma: a trial of the ECOG-ACRIN Research Group (E4412). 2019 International Conference on Malignant Lymphoma (Lugano, Switzerland).
  121. Jagadeesh D, Tsai D, Wei W, Wagner-Johnston N, Xie E, Berg S, Smith SE, Koff JL, Barot S, Hwang D, Kim S, Venugopal P, **Fenske T**, Sriram D, David K, Santapuram P, Reddy N, Dharnidharka V, Evens AM. Post-transplant lymphoproliferative disorders (PTLD) after solid organ transplant (SOT): survival and prognostication among 570 patients treated in the modern era, 2019 International Conference on Malignant Lymphoma (Lugano, Switzerland).
  122. Hamadani M, Sureada A, Ahn KW, Kharfan-Dabaja M, Litovich C, **Fenske TS**. Allogeneic hematopoietic cell transplantation in elderly (????years) non-Hodgkin lymphoma patients: a time trends analysis from the Center for International Blood and Marrow Transplant Research (CIBMTR). 2019 European Society of Blood and Marrow Transplantation Meeting (Frankfurt, Germany).
  123. Shah NN, Zhu F, Taylor C, Schneider D, Kruger W, Worder A, **Fenske TS**, Hamadani M, Johnson B, Dropulic B, Orentas RJ, Hari P. Clinical results of a first-in-human phase I study of bispecific anti-CD19, anti-CD20 chimeric antigen receptor modified (LV20.19CAR) T cells for relapsed, refractory, non-Hodgkin lymphoma. 2019 European Society of Blood and Marrow Transplantation Meeting (Frankfurt, Germany).
  124. Shah NN, Zhu F, Schneider D, Taylor C, Krueger W, Worden A, Longo WL, Hamadani M, **Fenske T**, Johnson B, Dropulic B, Orentas R, Hari P. Results of a phase I study of bispecific anti-CD19, anti CD20 chimeric antigen receptor (CAR) modified T cells for relapsed, refractory, non-Hodgkin lymphoma. 2019 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
  125. Bond DA, Switchenko JM, Maddocks K, Churnetski M, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Hill BT, Sawalha Y, Martin P, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Badar T, Guo J, Hamadani M, **Fenske TS**, Malacek M, Kahl BS, Flowers CR, Blum KA, Cohen JB. Outcomes

- following early relapse in patients with mantle cell lymphoma. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
126. Hill BT, Switchenko JM, Martin P, Churnetski M, Sawalha Y, Goyal S, Shanmugasundaram K, Calzada O, Kolla B, Bachanova V, Gerson JN, Barta SK, Maldonado E, Gordon M, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Ghosh N, Park SI, Epperla N, Bond D, Badar T, Blum KA, Guo J, Hamadani M, **Fenske TS**, Malecek M, Kahl BS, Flowers CR, Cohen JB. Maintenance rituximab is associated with improved overall survival in mantle cell lymphoma patients responding to induction therapy with bendamustine + rituximab (BR). 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  127. Epperla N, Switchenko JM, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta S, Gordon MJ, Danilov AV, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SO, Bond DA, Badar T, Blum KA, Hamadani M, **Fenske TS**, Malecek M, Martin P, Guo J, Kahl BS, Flowers CR, Cohen JB. Short time to treatment is associated with inferior survival in newly diagnosed patients with mantle cell lymphoma. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  128. Jagadeesh D, Majhail NS, Yizeng H, Ahn KW, Litovich C, **Fenske TS**, Sureda A, Kharfan-Dabaja MA, Hamadani M. Does addition of rituximab to BEAM conditioning improve outcomes of patients with diffuse large B-cell lymphoma undergoing autologous hematopoietic cell transplantation? 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  129. Shah NN, Zhu F, Schneider D, Krueger W, Worden A, Longo WL, Hamadani M, **Fenske TS**, Dropulic B, Orentas RJ, Hari P, Johnson B. Fresh Versus Cryopreserved/Thawed Bispecific Anti-CD19/CD20 CAR-T Cells for Relapsed, Refractory Non-Hodgkin Lymphoma. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  130. Romancik J, Switchenko JM, Shanmugasundaram K, Goyal S, Calzada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov A, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, **Fenske TS**, Malacek MK, Kahl BS, Martin P, Guo J, Flowers CR, Cohen JB. The impact of pre-diagnosis tobacco use in mantle cell lymphoma. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  131. Ahmed S, Ghosh N, Khanal M, Ahn KW, Litovich C, **Fenske TS**, Kharfan-Dabaja MA, Sureda A, Hamadani M. Comparison of reduced-intensity conditioning regimens for allogeneic hematopoietic cell transplantation for classical Hodgkin lymphoma: a CIBMTR analysis. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  132. Ghosh N, Ahmed S, Litovich C, Ahn KW, Khanal M, Kharfan-Dabaja MA, Sureda A, **Fenske TS**, Hamadani M. Comparison of reduced-intensity conditioning regimens for allogeneic hematopoietic cell transplantation in non-Hodgkin lymphoma: a CIBMTR analysis. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  133. Kim Y, Bagot M, Zinzani PL, Duvic M, Morris S, Kim E, Musiek A, Ortiz-Romero PL, Elmetts C, Eradat HA, Magnolo N . . . **Fenske TS** . . . Sokol M. Safety of mogamulizumab in mycosis fungoides and Sezary syndrome: final results of the phase 3 Mavoric study. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  134. Cohen J, Sswitchenko JM, Shanmugasundaram K, Goyal S, Calada O, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov A, Grover NS, Mathews S, Burkart M, Karmali R, Sawalha Y, Hill BT, Ghosh N, Park SI, Epperla N, Bond DA, Badar T, Blum KA, Hamadani M, **Fenske TS**, Malacek MK, Martin P, Guo J, Flowers CR, Kahl BS. Clinical trial participation is associated with improved overall survival in newly diagnosed patients with mantle cell lymphoma. 2019 American Society of Hematology Annual Meeting (Orlando, FL).
  135. Karmali R, Switchenko JM, Goyal S, Bachanova V, Gerson J, Barta SK, Danilov AV, Grover NS, Epperla N, Burkart M, Sawalha Y, Ghosh N, Bond DA, Maddocks KJ, Badar T, **Fenske T**, Guo J, Malecek M, Martin P, Cohen JB. Older patients with mantle cell lymphoma (MCL): Practice patterns and predictors of survival in the rituximab era. 2020 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
  136. Shah NN, Ahn KW, Litovich C, **Fenske T**, Hamadani M. Is autologous transplantation (autoHCT) in relapsed diffuse large B-cell lymphoma (DLBCL) patients achieving only a PET/CT positive partial remission (PR) appropriate in the CAR-T cell era? 2020 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
  137. Xu H, Chaney K, Johnson BD, **Fenske TS**, Hamadani M, Dropulic B, Schneider D, Hari P, Shah NN.

- Single-Cell Cytokine Analysis of LV20.19 Bispecific CAR T-Cell Products from a Phase I Clinical Trial. 2020 American Society of Hematology Annual Meeting (San Diego, CA).
138. Wang ML, Shah N, Alencar AJ, Gerson JN, Patel MR, Fakhri, B, Jurczak W, Tan X, Lewis K, **Fenske T**, Coombs CC, Flinn I, Lewis D, Le Gouill S, Palomba M, Woyach J, Pagel JM, Lamanna N, Cohen JB, Barve MA, Ghia P, Eyre TA, Yin M, Nair B, Tsai DE, Ku NC, Mato AR, Cheah CY. LOXO-305, Next Generation A Highly Selective and Non-covalent Bruton's Tyrosine Kinase Inhibitor In Previously Treated Mantle Cell Lymphoma, Waldenstrom's Macroglobulinemia, And Other Non-Hodgkin Lymphomas: Results From The Phase 1/2 BRUIN Study. 2020 American Society of Hematology Annual Meeting (San Diego, CA).
  139. Luo T, Hamadani M, **Fenske TS**, Hari P, Shah N. Allogeneic Transplant Outcomes for T-cell Lymphomas. 2020 American Society of Hematology Annual Meeting (San Diego, CA).
  140. Galvez C, Karmali R, Hamadani M, Gordon L, Winter J, Ma S, Nelson V, Palmer B, **Fenske TS**, Shah NN, Jagadeesh D, Evens A, Klein A, Helenowski I, Jovanovic B, Petrich A, Pro B. A Phase I-II Trial of DA-EPOCH-R Plus Ixazomib as Frontline Therapy for Patients with MYC-aberrant Lymphoid Malignancies: The DACIPHOR Regimen. 2020 American Society of Hematology Annual Meeting (San Diego, CA).
  141. Karmali R, Switchenko JM, Goyal S, Churnetski MC, Kolla B, Bachanova V, Gerson JN, Barta SK, Gordon MJ, Danilov AV, Grover NS, Epperla N, Mathews S, Burkart M, Sawalha Y, Hill BT, Ghosh N, Park SI, Bond DA, Maddocks KJ, Badar T, **Fenske TS**, Hamadani M, Guo J, Malacek M, Kahl BS, Martin P, Blum KA, Flowers CR, Cohen JB. Practice Patterns and Predictors of Survival in Older Patients with Mantle Cell lymphoma (MCL) in the Rituximab Era. 2020 American Society of Hematology Annual Meeting (San Diego, CA).
  142. Nowakowski G, Leslie LA, Joffe E, Rosenthal A, Lunning M, Patel K, Landsburg D, **Fenske T**, Ramchandren R, Ramakrishnan P, Skarbnik A, Martinez E, von Roemeling R, Tun HW. A Multi-Center, Dose-Finding Study to Assess Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CA-4948 an IRAK4 inhibitor in combination with ibrutinib (BTKi), in Patients with Relapsed or Refractory Hematologic Malignancies. 2020 American Society of Hematology Annual Meeting (San Diego, CA).
  143. Shah NN, Zurko J, **Fenske TS**, Hamadani M, Schneider D, Xu H, Chaney K, Dropulic B, Johnson BD, Hari P. Clinical and Manufacturing Outcomes of LV20.19 CAR T-cells Expanded in IL-2 versus IL-7 & IL-15. 2021 Transplant & Cellular Therapy Meeting.
  144. Zurko J, Xu H, Chaney K, **Fenske TS**, Hamadani M, Schneider D, Dropulic B, Hari P, Johnson B, Shah NN. 8-day versus 12-day manufacturing of LV20.19 CAR T-cells impacts single cell cytokine profiles without increasing severity of toxicities. 2021 International Society of Cell and Gene Therapy Meeting.
  145. Gerson JN, Handort E, Villa D, Gerrie AS, Li S, Medeiros J, Wang M, Cohen JB, Calzada O, Churnetski M, Hill BT, Sawalha Y, Hernandez-Ilizaliturri FJ, Kothari S, Vose JM, Bast M, **Fenske TS**, Rao Gari SN, Maddocks KJ, Bond D, Bachanova V, Kolla B, Chavez J, Shah B, Lansigan F, Donovan AM, Wagner-Johnston N, Messer M, Mehta A, Anderson JK, Reddy N, Kovach AE, Landsburg DJ, Glenn M, Inwards DJ, Ristow K, Karmali R, Kaplan JB, Caimi PF, Rajguru S, Evens A, Klein A, Umyarova E, Amengual JE, Lue JK, Diefenbach C, Epperla N, Barta SK. Survival following first relapse in younger patients with mantle cell lymphoma. 2021 International Conference on Malignant Lymphoma (Lugano, Switzerland).
  146. Rezaadeh A, Szabo A, Monahan K, Khurana A, Inwards D, Lunning M, Cashen A, Bartlett B, Caimi P, Rodgers T, Barr P, Chowdhury SM, Epperla N, Mendries H, Hill B, Oh TS, Karmali R, Chang J, Goyal G, Rao Gari SN, Parsons B, Isaac K, Portell C, Siker M, King DM, **Fenske TS**. Outcomes of Primary Bone Diffuse Large B-Cell Lymphoma in the Rituximab Era: A Multicenter Retrospective Analysis. 2021 American Society of Hematology Annual Meeting (Atlanta, GA).
  147. Romancik JT, Goyal S, Gerson J, Ballard H, Sawalha Y, Bond DA, Rogalski M, Greenwell IB, Martin P, Van Besien K, Yamshon S, Karmali R, Nizamuddin I, Torka P, Chow V, Gopal A, Ghosh N, Moyo T, **Fenske TS**, \*Rezaadeh A, Grover N, Maddocks KJ, Jacobson C, Cohen JB. Analysis of outcomes and predictors of response in patients with relapsed mantle cell lymphoma treated with brexucabtagene autoleucel. 2021 American Society of Hematology Annual Meeting (Atlanta, GA).
  148. Shah NN, Zurko J, Schneider D, Hamdani N, **Fenske TS**, Bryon Johnson B, Hari P. Results from a Phase 1/2 Trial of IL7/IL15-Expanded Bispecific LV20.19 CAR T-cells for Relapsed, Refractory B-cell Non-Hodgkin Lymphoma. 2021 American Society of Hematology Annual Meeting (Atlanta, GA).
  149. Zurko JC, Xu H, Chaney K, **Fenske TS**, Hamadani M, Schneider D, Hari P, Johnson B, Shah NN.



- Bispecific LV20.19 CAR T-cells expanded in IL-7 and IL15 have greater polyfunctionality and polyfunctional strength than CAR T-cells expanded in IL-2. 2021 American Society of Hematology Annual Meeting (Atlanta, GA).
150. Kahl BS, Hong F, Peterson C, Swinnen LJ, Habermann TM, Schuster SJ, Weiss W, Fishkin PA, Ehmann WC, **Fenske TS**, Williams ME. Long Term Follow Up of the RESORT Study (E4402): A Randomized Phase III Study Comparing Two Different Rituximab Dosing Strategies for Low Tumor Burden Follicular Lymphoma. 2021 American Society of Hematology Annual Meeting (Atlanta, GA).
  151. Wang ML, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan Z, Lewis K, **Fenske T**, Coombs CC, Flinn I, Lewis D, Le Gouill S, Palomba ML, Woyach J, Pagel JM, Lamanna N, Cohen JB, Barve MA, Ghia P, Eyre TA, Zinzani PL, Ujjani C, Koh Y, Iizutsu K, Lech-Maranda E, Tam C, Sundaram S, Yin M, Nair B, Tsai DE, Balbas M, Mato AR, Cheah CY. Pirtobrutinib, a next generation, highly selective, non-covalent BTK inhibitor in previously treated mantle cell lymphoma: Updated results from the phase 1/2 BRUIN study. 2021 American Society of Hematology Annual Meeting (Atlanta, GA).
  152. Kim J, **Fenske TS**, McCurdy T, Chandra AB, Penberthy D, Gracie-King L, Viens M, Ocana V. A multiphase continuing education and quality improvement initiative to tailor treatment plans for patients with follicular lymphoma. 2022 American Society of Clinical Oncology Annual Meeting (Chicago, IL).
  153. Shah NN, Zurko J, Hamadani H, Hari P, Longo W, Johnson B, **Fenske TS**. Phase 1/2 trial of bispecific LV20.19 CAR T-cells for relapsed, refractory mantle cell lymphoma. 2022 International Ultmann Chicago Lymphoma Symposium (Chicago, IL).
  154. Rezazadeh A, Hamadani M, Shah NN, **Fenske TS**. Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma. 2022 International Ultmann Chicago Lymphoma Symposium (Chicago, IL).
  155. Cohen JB, Shah NN, Alencar AJ, Gerson JN, Patel MR, Fakhri B, Jurczak W, Tan XN, Lewis KL, **Fenske T**, Coombs CC, Flinn IW, Lewis DJ, Gouill SL, Palomba ML, Woyach JA, Pagel JM, Lamanna N, Barve MA, Ghia P, Eyre TA, Zinzani PL, Ujjani CS, Koh Y, Izutsu K, Lech-Maranda E, Tam CS, Sundaram S, Yin M, Nair B, Tsai DE, Balbas M, Mato AR, Cheah CY, Wang ML. Pirtobrutinib, a highly selective non-covalent (reversible) BTK inhibitor in previously treated mantle cell lymphoma: updated results from the phase 1/2 BRUIN study. Society of Hematologic Oncology Annual Meeting, 2022.
  156. Rezazadeh A, Hamadani M, Shah NN, **Fenske TS**. Immunoglobulin high throughput sequencing (Ig-HTS) minimal residual disease (MRD) analysis is an effective surveillance tool in patients with mantle cell lymphoma. 2022 American Society of Hematology Annual Meeting (New Orleans, LA).
  157. Shah NN, Furqan F, Szabo A, Neumann J, Longo W, Hari P, Schneider D, Johnson B, **Fenske TS**, Hamadani M. 8-day versus 12-day manufactured LV20.19 CAR T-cells for B-cell non-Hodgkin lymphoma. 2022 American Society of Hematology Annual Meeting (New Orleans, LA).
  158. Furqan F, Xu H, Zurko J, **Fenske TS**, Hamadani M, Johnson B, Shah NN. Single cell cytokine analyses of bispecific, tandem, anti-CD20, anti-CD19 CAR T-cells from patients with relapsed, refractory B-cell malignancies. 2022 American Society of Hematology Annual Meeting (New Orleans, LA).
  159. Furqan F, **Fenske TS**, Longo W, Johnson B, Hamadani M, Shah N. MRD status by clonoSEQ is a poor predictor of long-term outcomes after bispecific LV20.19 CAR T-cell therapy for relapsed, refractory B-cell NHL. 2022 American Society of Hematology Annual Meeting (New Orleans, LA).
  160. Shah NN, Furqan F, Szabo A, Neumann J, Schneider D, Johnson B, Hamadani M, **Fenske TS**. Results from a phase 1/2 study of tandem, bispecific anti-CD20/ anti-CD19 (LV20.19) CAR T-cells for mantle cell lymphoma. 2022 American Society of Hematology Annual Meeting (New Orleans, LA).
  161. Shah NN, Furqan F, Szabo A, Neumann J, Hari P, Schneider, Johnson B, Hamadani M, **Fenske TS**. Results from a phase 1/2 study of tandem, bispecific anti-CD20/anti-CD19 (LV20.19) CAR T-cells for mantle cell lymphoma. 2023 Transplant & Cellular Therapy Meeting.
  162. Furqan F, Aschenbrenner E, Talano J, Moskp A, Longo W, Johnson B, **Fenske TS**, Hamadani M, Shah NN. Clinical characteristics and patient outcomes with HLH-like toxicities after CD19-based CAR T-cell therapy. 2023 Transplant & Cellular Therapy Meeting.
  163. Furqan F, Johnson B, Hamadani M, **Fenske TS**, Shah NN. Bispecific anti-CD20/anti-CD19 (LV20.19) CAR T-cells for Richter's transformation. 2023 Transplant & Cellular Therapy Meeting.
  164. Shah NN, Szabo A, Rajguru S, Devata S, Howard M, Pereira D, Longo W, Siddiqui N, Hamadani M, **Fenske TS**, Fletcher C. Phase II trial of split-dose R-CHOP for older patients with diffuse large B-cell lymphoma (DLBCL). 2023 American Society of Clinical Oncology Annual Meeting (Chicago, IL).

165. Price SN, Lee JW, Gareen IF, Kircher SM, Kumar SK, Mayer I, Saba NF, **Fenske TS**, Atkins MB, Hodi FS, Kyriakopoulos CE, Tempany-Afdhal CM, Shahafelt TD, Park ER, Wagner LI. Tobacco use, symptom burden, and symptom management perspectives among adults with cancer: baseline results from 9 ECOG-ACRIN therapeutic clinical trials. 2023 American Society of Preventative Oncology Annual Meeting (San Diego, CA).
166. Shah NN, Furqan F, Szabo, Kearl T, Zamora A, Neumann J, Hari P, Schneider D, Johnson B, Hamadani M, **Fenske TS**. Phase 1/2 Trial Utilizing Adaptive Manufacturing of LV20.19 CAR T-cells for Relapsed, Refractory Mantle Cell Lymphoma. 2023 American Society of Hematology Annual Meeting (San Diego, CA).
167. Ahmed R, Anyanwu P, Hamadani M, Shah N, Devata S, Longo W, Bovi J, Siker M, Schultz C, **Fenske TS**. Real-world experience with RTOG 0227 induction for first-line therapy of primary CNS lymphoma (PCNSL). 2023 American Society of Hematology Annual Meeting (San Diego, CA).
168. Andreadis C, Geyer S, **Fenske T**, Stiff P, Hill B, His E, Bobek O, Little R, Perles M, Devine S, Leonard J, Bartlett. Ibrutinib Added to Standard Conditioning and As Consolidation Following Autologous Hematopoietic Cell Transplantation (Auto-HCT) for Relapsed/Refractory Activated-B-Cell Subtype Diffuse Large B-Cell Lymphoma (ABC-DLBCL): Results from the US Intergroup Double-Blind Randomized Phase III Study Alliance A051301/BMT-CTN 1201. 2023 American Society of Hematology Annual Meeting (San Diego, CA).
169. Epperla N, Switchenko J, Bachanova, V, Barta SK, Danilov AV, Grover NS, Karmali R, Hill BT, Ghosh N, **Fenske TS**, Martin P, Kahl BS, Flowers CR, Link BK, His ED, Maddocks K, Blum KA, Cerhan JR, Habermann TM, Seyer S, Bartlett NL, Leonard JP, Naurer MJ, Cohen J. A Ki-67 cut-off of 50% is a better predictor of survival outcomes in patients with mantle cell lymphoma (MCL): Pooled analysis from ALLIANCE/CALGB 50403 and MCL-RWS. 2023 American Society of Hematology Annual Meeting (San Diego, CA).
170. Wang Y, Larson MC, Farooq U, Ekberg S, Smedby KE, Simonsen MR, Niemann CU, Zhao EJ, Gerrie A, Switchenko JM, Bond DA, Bachanova V, Barta SK, Hill BT, Martin P, Danilov AV, Grover NS, Karmali R, Ghosh N, **Fenske TS**, Kahl BS, Albertsson-Lindblad A, Glimelius I, Al-Mashhadi AL, Larsen TS, Maddocks KJ, Link BK, Paludo J, Nowakowski GS, Habermann TM, Maurer MJ, Villa D, Cohen JB, El-Galaly TC, Jerkeman M, Cerhan JR. An International Multicohort Study of Conditional Survival and Cause of Death After Achieving Event-Free Survival at 24 Months in Patients with Mantle Cell Lymphoma. 2023 American Society of Hematology Annual Meeting (San Diego, CA).
171. Furqan F, Szabo A, Kearl T, Zamora A, Dwinell M, Neumann J, Hari P, Schneider D, Hematti P, Johnson B, Hamadani M, **Fenske TS**, Shah NN. Fresh versus Cryopreserved LV20.19 CAR T-cell therapy for Relapsed, Refractory DLBCL and Follicular Lymphoma. 2023 American Society of Hematology Annual Meeting (San Diego, CA).
172. Tun AM, Patel R, St-Pierre F, Ouchveridze J, Niu A, Obasi J, Rosenthal A, Pophali PA, **Fenske T**, Karmali R, Ahmed S, Johnston PB. Chimeric antigen receptor T-cell therapy in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a multicenter study. 2023 American Society of Hematology Annual Meeting (San Diego, CA).
173. Nguyen C, McAllister D, Poimenidou M, Johson BD, **Fenske TS**, Hematti P, Hamadani M, Schneider D, Kearl T, Dwinell MB, Shah NN. Cryopreservation of LV20.19 CAR T cells impacts T cell functionality by scRNAseq. 2023 International Society for Cell and Gene Therapy Meeting (Paris, France)